EurekaMag PDF full texts Chapter 35,452

Kaneda, M.; Ishii, K.; Rockland, K.S.; Hashikawa, T. 2002: P2x7 purinergic receptors exist in the neuron in the monkey retina. Society for Neuroscience Abstract Viewer and Itinerary Planner : Abstract No 843 5

Santos Berrios, C.; Weisman, G.A.; Gonzlez, F.A. 2002: P2x7 receptor induces gene expression. Society for Neuroscience Abstract Viewer and Itinerary Planner: Abstract No. 338-6

Murphy, T.J.; Abbott, K. 1999: P2y receptors activate the cyclosporin A sensitive transcription factor NFAT in rat vascular smooth muscle cells Influence on interleukin-6 gene induction. FASEB Journal 13(4 Part 1): A47

Mantuano, M.B.; Henriques Pons, A.; Araujo Jorge, T.C.; Coutinho Silva, R.; Persechini, P.M. 2000: P2z/p2x7 modulation in experimental Trypanosoma cruzi infection Possible involvement in thymic atrophy and evasion mechanism from macrophages. Memorias do Instituto Oswaldo Cruz 95(Suppl 2): 183

Brankack, J.; Talnov, A.; Shionoya, K.; Matsumoto, G. 2000: P3 and theta frequency shift in rat emerge with acquisition of response habits. European Journal of Neuroscience 12(Suppl 11): 162

Russmann, T.; Bradley, M.M.; Junghoefer, M.; Keil, A.; Lang, P.J. 2000: P3 response to an acoustic startle probe is modulated by emotional sounds. Psychophysiology 37(Suppl 1): S84

Webster, K.; Colrain, I. 2000: P3-specific amplitude reductions to respiratory and auditory stimuli in asthmatics. Psychophysiology 37(Suppl 1): S102

Boothroyd, J.C.; Burg, J.L. 1999: P30 peptides of Toxoplasma gondii. Official Gazette of the United States Patent and Trademark Office Patents 1218(2): 1404

Miltner, W.H.R.; Krieschel, S.; Gutberlet, I. 2000: P300 A signature for threat processing in phobic subjects. Psychophysiology 37(Suppl 1): S71

Enoch, M.A.; White, K.; Harris, C.; Rohrbaugh, J.; Goldman, D. 1999: P300 ERP variation in a community population Relationship to alcoholism and anxiety disorders. Alcoholism Clinical and Experimental Research 23(5 Suppl): 68A

Fan, L.; Zhu, S.; Frantz, C.N. 1999: P300 abrogates the effects of iron chelation on N-myc expression and apoptosis in human neuroblastoma cells. Proceedings of the American Association for Cancer Research Annual Meeting 40: 15

Malone, S.M.; Iacono, W.G.; Carlson, S.R. 2000: P300 amplitude at age 17 predicts the subsequent development of substance use disorders. Psychophysiology 37(Suppl 1): S66

Mertens, R.; Allen, J.J.B. 2000: P300 amplitude does not distinguish true from false memories when subjects rate confidence in the Deese paradigm. Psychophysiology 37(Suppl 1): S71

Yokoyama, K.K. 2001: P300 and ATF-2 facilitate transcription of c-jun gene during retinoic acid -induced differentiation of embryonal carcinoma cells. Abstracts of Papers American Chemical Society 221(1-2): AGFD 22

Bordoli, L.; Stern, D.; Lutz, W.; Huesser, S.; Eckner, R. 1999: P300 and CBP in mouse development and growth control. Biochemical Society Transactions 27(3): A64

Wada, H.; Hasegawa, K.; Morimoto, T.; Sasayama, S. 2000: P300 and PCAF acetylate GATA-4 in endothelin-1 transcription. Journal of Molecular and Cellular Cardiology 32(11): A107

Sakoda, T.; Naka, T.; Abe, T.; Fujioka, Y.; Tsujino, T.; Iso, T.; Hamamori, Y.; Ohyanagi, M. 2003: P300 and serum response factor are involved in Rho kinase-mediated c-fos gene expression in cardiac myocytes. Circulation 108(17): IV116

Segalowitz, S.J.; Wintink, A.J.; Cudmore, L.J. 2000: P300 anterior-posterior slope Effects of task complexity and habituation. Psychophysiology 37(Suppl 1): S89

Gilbert, D.G.; Mcclernon, F.J.seph 2000: P300 attenuation fails to recover after 31 days of tobacco abstinence. Psychophysiology 37(Suppl 1): S43

Anokhin, A.P.; Vedeniapin, A.B. 2001: P300 brain potential in psychiatric genetics A neurobehavioral model of diathesis. American Journal of Medical Genetics 105(7): 630

Fernandez Lorente, Jose; Martino, M. Elena; Romero Vives, Maria; De Vicente, Emilio; Barcena, Rafael; De Blas, Gemma; Gaztelu, Jose M. 2002: P300 cognitve evoked potential and EEG alterations persist after liver transplantation. Journal of Hepatology 36(Suppl 1): 187

Kawamura, T.; Hasegawa, K.; Morimoto, T.; Akao, M.; Hirai, M.; Ehara, N.; Kita, T. 2003: P300 controls the bcl-2 transcription in association with calcineurin-dependent signaling during myocardial cell survival. Cell Structure and Function 28(4): 371

Kawamura, T.; Iwai Kanai, E.; Yanazume, T.; Ehara, N.; Hasegawa, K. 2002: P300 controls the transcription of the bcl-2 gene and associates with calcineurin-dependent signaling during the protection against myocardial cell apoptosis. Circulation 106(19): II236

Debes, J.D.; Sebo, T.J.; Murphy, L.M.; Haugen, D.A.na L.; Lohse, C.M.; Tindall, D.J. 2003: P300 in androgen-independent prostate cancer From androgen receptor transactivation to cancer progression. Proceedings of the American Association for Cancer Research Annual Meeting 44: 382-383

Houston, R.; Bauer, L. 2003: P300 latency in HIV-1 seropositive patients The contribution of premorbid risk factors. Alcoholism Clinical and Experimental Research 27(5 Suppl): 19A

Debes, J.D.; Schmidt, L.J.; Huang, H.; Tindall, D.J. 2002: P300 mediates Interleukin-6-dependent transactivation of the androgen receptor. Proceedings of the American Association for Cancer Research Annual Meeting 43: 161

Thimmapaya, B.; Kolli, S.; Buchmann, A.; Anderson, L.; Williams, J.; Weitzman, S. 2000: P300 negatively regulates G0/G1 phase of the cell cycle by repressing c-myc. Proceedings of the American Association for Cancer Research Annual Meeting 41: 562

Villagra, A.; Sierra, J.; Olate, J.; Van Wijnen, A.; Lian, J.; Stein, G.; Stein, J.; Montecino, M. 2002: P300 requires Runx2/Cbfa1 and the Vitamin D3 receptor to regulate bone specific osteocalcin expression but not its intrinsic histone acetyl transferase activity. Journal of Bone and Mineral Research 17(Suppl 1): S438-S439

Rosenfeld, J.P.; Miller, A.; Rao, A.; Soskins, M. 2000: P300 scalp distributions in detection of deception. Psychophysiology 37(Suppl 1): S19

De Luca, Antonio; Severino, Anna; De Paolis, Paola; Cottone, Giuliano; De Luca, Luca; De Falco, Maria; Porcellini, Antonio; Volpe, Massimo; Condorelli, Gianluigi 2003: P300/cAMP-response-element-binding-protein -binding protein modulates co-operation between myocyte enhancer factor 2A and thyroid hormone receptor-retinoid X receptor. Biochemical Journal 369(3): 477-484, 1 February

Mancuso, M.; Leone, M.; Filosto, M.; Tognoni, G.; Siciliano, G.; Nichelli, P.; Murri, L. 2003: P301L Tau mutation and non-Alzheimer dementias in Italy. Acta Neurologica Scandinavica 108(5): 379-380

Stopar, M.; Doloan, V.; Eerjav Tanoek, M.; Breskvar, K.; Kroionik, C.; Battelino, T. 2000: P30L mutation linked to gene conversion in CYP21 gene may cause severe form of CAH. European Journal of Human Genetics 8(Suppl 1): 138

Mariani, L.; Mcdonough, W.S.; Beaudry, C.; Hoelzinger, D.B.; Ross, K.R.; Kaczmarek, E.; Coons, S.W.; Giese, A.; Seiler, R.W.; Berens, M.E. 2001: P311 and death associated protein 3 Glioblastoma invasion genes identified by laser capture microdissection, differential dysplay, and QRT-PCR. Proceedings of the American Association for Cancer Research Annual Meeting 42: 523-524

Desi, P.; Zhe, X.; Taylor, G.A.; Schuger, L. 2001: P311, a small protein with several PEST motifs, plays a role in myofibroblast differentiation. Molecular Biology of the Cell 12(Suppl): 368a-369a

Vahakangas, K.H.; Bennett, W.P.; Castren, K.; Welsh, J.A.; Khan, M.A.; Alvanja, M.; Harris, C.C. 1999: P32 Mutations in lung cancers from non-smoking women. Proceedings of the American Association for Cancer Research Annual Meeting 40: 279

Sorbera, L.A.; Revel, L.; Castaner, J. 2001: P32/98 Antidiabetic, dipeptidyl-peptidase IV inhibitor. Drugs of the Future 26(9): 859-864

Cheung, K.J.; Ho, V.; Li, G. 2000: P33ING1 involvement in cellular stress response and its in vivo relationship with p53. Journal of Investigative Dermatology 114(4): 854

Ahmed, I.A.del Rahim, M.; Nouman, G.; Kelly, S.B.; Anderson, J.J.; Angus, B.; Lunec, J. 2002: P33ING1 nuclear expression and TP53 gene mutation in colorectal cancer and their association with clinical outcome. Proceedings of the American Association for Cancer Research Annual Meeting 43: 713

Cheung, K.; Lin, P.; Ho, V.; Li, G. 2001: P33ING1 role in DNA repair. Journal of Investigative Dermatology 117(2): 522

Hisanaga, S.C.; Honma, N.; Yamakawa, E.; Takeshita, S.; Kishimoto, T. 2001: P35 Cdk5 activator binding protein. Cell Structure and Function 26(5): 486

Dell'acqua, G.; Mann, M.J.; Dzau, V.J. 1999: P35 Identification, characterization and functional studies of a novel p53 alternative splice product in the rat. FASEB Journal 13(7): A1480

Kuraya, M.; Endo, Y.; Matsushita, M.; Fujita, T. 2000: P35-related gene expression in neutrophils as well as monocytes. Immunopharmacology 49(1-2): 11

Kesavapany, S.; Amin, N.; Zheng, Y.; Jaffe, H.; Nijhara, R.; Gutkind, S.; Takahashi, S.; Kulkarni, A.; Grant, P.; Pant, H.C. 2004: P35/Cdk5 phosphorylates RasGRF2 regulating RasGRF2-mediated Rac signaling and ERK1/2 activity. Journal of Neurochemistry 88(Suppl 1): 81

Ching, Y.P.; Wang, J.H.C. 2004: P35NCK5A binding proteins. Official Gazette of the United States Patent and Trademark Office Patents 1283(4)

Dockrell, M.E.C.; Duvaz, I.N.; Newman, D.J. 2003: P38 MAP kinase activation by TGF-beta 1 in human proximal tubular cells. Journal of the American Society of Nephrology 14(Abstracts Issue): 90A

Carlson, C.; Rondinone, C. 2003: P38 MAP kinase controls GLUT4 protein levels through regulation of interleukin-6 Evidence for an IL-6 autocrine loop in human adipocytes. Diabetes 52(Suppl 1): A278

Williams, W.V.; Prabhakar, U.; Fullerton, T.; Sharma, S.; Erikis, E.; Sharma, A.; Lee, J.C.; Boike, S.; Davis, H.M.; Truneh, A.; Jorkasky, D.K. 2000: P38 MAP kinase inhibition in rheumatoid synovium and ex vivo Effects on cytokine production. FASEB Journal 14(6): A1211

Ding, X.Z.; Adrian, T.E. 2000: P38 MAP kinase inhibition induces proliferation through activation of MEK/ERK signaling in the pancreatic cancer cell line, PANC-1. Pancreas 21(4): 438

Cheng, S.; Goldstein, D.M.; Martin, T.A. Trejo; Sjogren, E.B. 2001: P38 MAP kinase inhibitors. Official Gazette of the United States Patent and Trademark Office Patents 1252(2)

Adams, J.L.; Bower, M.J.; Boehm, J.C.; Gallagher, T.F.; Hall, R.; Zhao, B.; Lee, J.C. 2001: P38 MAP kinase inhibitors From biochemical tools to clinical trials. Cellular and Molecular Biology Letters 6(2B): 450-451

Jeohn, G.-H.; Cooper, C.L.; Wilson, B.; Chang, R.C.C.; Jang, K.-J.; Kim, H.-C.; Liu, B.; Hong, J.-S. 2002: P38 MAP kinase is involved in lipopolysaccharide-induced dopaminergic neuronal cell death in rat mesencephalic neuron-glia cultures. Annals of the new York Academy of Sciences 962: 332-346

Li, X.; Udagawa, N.; Itoh, K.; Suzawa, T.; Suda, K.; Murase, Y.; Nishihara, T.; Suda, T.; Takahashi, N. 2001: P38 MAP kinase is involved in osteoclast differentiation but not in osteoclast activation. Journal of Bone and Mineral Research 16(Suppl 1): S384

Chen, W.; Bowden, G.T. 1999: P38 MAP kinase is necessary for UVB irradiation induced c-fos gene expression in human keratinocytes. Proceedings of the American Association for Cancer Research Annual Meeting 40: 553

Cuervo, C.S.; Harris, K.W.; Kallman, L.; Vaananen, K.; Selander, K. 2002: P38 MAP kinase is required for bone metastasis, but not locally aggressive growth, in a mouse model of metastatic breast cancer. Journal of Bone and Mineral Research 17(Suppl 1): S409

Hayes, S.; Bergan, R. 2002: P38 MAP kinase is required for transforming growth factor beta-mediated cell adhesion in metastatic prostate cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting 43: 22

Chen, W.; Bowden, G.T. 2000: P38 MAP kinase is required for ultraviolet-B irradiation induced activator protein-1 activation in human keratinocytes. Proceedings of the American Association for Cancer Research Annual Meeting 41: 249

Aker, S.; Konietzka, I.; Belosjorow, S.; Heusch, G.; Schulz, R. 2002: P38 MAP kinase phosphorylation and apoptosis in pacing-induced heart failure. European Heart Journal 23(Abstract Suppl): 200

Somervaille, T.C.P.; Linch, D.C.; Khwaja, A. 2001: P38 MAP kinase regulates both differentiation and apoptosis in primary human erythroid cells. Blood 98(11 Part 1): 78a-79a

Kan, H.; Xie, Z.; Olness, E.; Finkel, M.S. 2002: P38 MAP kinase regulates negative inotropic effect of HIV gp120 on cardiac myocytes through Troponin I phosphorylation. FASEB Journal 16(4): A570

Segawa, M.; Sakaida, I.; Terai, S.; Aoyagi, M.; Sakaguchi, E.; Kayano, K.; Okita, K. 2001: P38 MAP kinase regulates the production of type IV collagenase in human hepatic stellate cell line LI90 and hepatic adenocarcinoma cell line SK-HEP-1. Hepatology 34(4 Pt 2): 497A

Touyz, R.M.; He, G.; Wu, X.H.; Schiffrin, E.L. 2000: P38 MAP kinase regulates vascular smooth muscle cell collagen synthesis by Ang II in SHR but not in WKY. Hypertension 36(4): 707

Tuli, R.; Seghatoleslami, M.R.; Tuli, S.; Howard, M.S.; Danielson, K.G.; Tuan, R.S. 2002: P38 MAP kinase regulation of AP-2 binding in TGF-beta1-stimulated chondrogenesis of human trabecular bone-derived cells. Annals of the new York Academy of Sciences 961: 172-177

Sayama, K.; Hanakawa, Y.; Shirakata, Y.; Yamasaki, K.; Hashimoto, K. 2000: P38 MAP kinase, but not protein kinase C nor NF-kappaB, is involved in ASK1-induced keratinocyte differentiation. Journal of Dermatological Science 23(3): 202

Chakravarty, D.; Kultz, D. 2001: P38 MAP kinase-mediated gene repression during hyperosmotic stress. FASEB Journal 15(5): A850

Nebreda, A.R.; Porras, A. 2000: P38 MAP kinases: beyond the stress response. Trends in Biochemical Sciences 25(6): 257-260

Dominguez, C. 2003: P38 MAP-kinase An exciting target for the treatment of inflammatory diseases. Inflammation Research 52(Suppl 2): S 89

D.L.ozzo, G.; Dhadwal, A.K.; Willis, A.; Rangos, S.G.; Chen, A.; Dudrick, S.J.; Sumpio, B.E. 2000: P38 MAP-kinase activation and vascular smooth muscle cell migration following nicotine exposure. FASEB Journal 14(4): A33

Larsen, K.I.; Ponomareva, L.V.; Wang, W.; Falany, M.L.; Williams, J.P. 2002: P38 MAP-kinase mediates glucose-dependent transcriptional regulation of osteoclast H+-ATPase expression. Journal of Bone and Mineral Research 17(Suppl 1): S352

Lochner, A. 2001: P38 MAPK activation Trigger or mediator in ischaemic preconditioning ?. Journal of Molecular and Cellular Cardiology 33(6): A70

Liu, R.Y.; Chun, F.; Liu, G.; Olashaw, N.E.; Zuckerman, K.S. 2000: P38 MAPK activation is required for autocrine TNF-alpha-induced Hut-78 cell proliferation. Proceedings of the American Association for Cancer Research Annual Meeting 41: 206

Berti Mattera, L.N.; Harwalkar, S.; Hughes, B.; Almhanna, K. 2001: P38 MAPK and Ca2+-independent PLA2 mediate cytoskeletal reorganization triggered by endothelins in Schwann cells. Journal of Neurochemistry 78(Suppl 1): 29

Cao, W.; Cheng, L.; Harnett, K.M.; Bitar, K.N.; Behar, J.; Biancani, P. 2001: P38 MAPK and HSP27 in ACh-induced contraction of cat esophageal circular smooth muscle. Gastroenterology 120(5 Suppl 1): A 219

Antlsperger, D.S.M.; Dirsch, V.M.; Vollmar, A.M. 2002: P38 MAPK and JNK are activated, but do not mediate ajoene-induced apoptosis. Naunyn-Schmiedeberg's Archives of Pharmacology 365(Suppl 1): R13

Lai, X.; Ding, G.; Reddy, K.; Kasinath, B.; Singhal, P. 2002: P38 MAPK and JNK oppositely regulate ANG II-induced apoptosis in human glomerular visceral epithelial cells. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 293A

Bell, J.R.; Eaton, P.; Shattock, M.J. 2001: P38 MAPK and ischemic preconditioning Confounding effects of stabilization time and DMSO. Circulation 104(17): 2; 101

Oh, D.; Ciaraldi, T.; Sathyaprakash, R.; Chaudhary, S.; Christiansen, L.; Mudaliar, S.; Henry, R. 2003: P38 MAPK expression and phosphorylation in human tissues Modulation by insulin, obesity and type 2 diabetes. Diabetes 52(Suppl 1): A52

Barone, F.C.; Irving, E.A.; Ohlstein, E.H.; White, R.F.; Feuerstein, G.Z.; Kumar, S.; Lee, J.C.; Smith, B.R.; Adams, J.L.; Roberts, J.; Reith, A.D.; Hunter, A.J.; Hadingham, S.J.; Parsons, A.A. 1999: P38 MAPK in focal stroke selective inhibitor reduces brain injury and neurological deficits. Society for Neuroscience Abstracts 25(1-2): 1060

Kogiso, T.; Nagahara, H.; Shiratori, K. 2003: P38 MAPK induced G1 cell cycle arrest through up-regulation of p21cip1 in TGF-b-treated human HCCs. Hepatology 38(4 Suppl 1): 572A

Behr, T.M.; Nerurkar, S.S.; Nelson, A.H.; Lee, J.; Woods, T.; Chandra, S.; Brooks, D.; Angermann, C.E.; Sackner Bernstein, J.D.; Willette, R.N. 2001: P38 MAPK inhibition halts hypertensive end organ damage and premature mortality in a rat model of cardiac hypertrophy and dysfunction. European Heart Journal 22(Abstract Suppl): 31

Krum, H.; See, F.; Tzanidis, A.; Martin, P. 2001: P38 MAPK inhibition improves intracardiac haemodynamic parameters and attenuates pathological collagen deposition in a rat model of heart failure post-MI. European Heart Journal 22(Abstract Suppl): 234

Medicherla, S.; Protter, A.; Mangadu, R.; Almirez, R.; Ma, J.; Dugar, S.; Mavunkel, B.; Perumattam, J.; Schreiner, G. 2003: P38 MAPK inhibitor prevents the development of type-1 diabetes and alleviates hyperglycemia in NOD mice A preliminary report. Diabetes 52(Suppl 1): A126-A127

Matos, T.J.; Duarte, C.B.; Carvalho, A.P.; Lopes, M.C. 2001: P38 MAPK is activated by the chemical sensitizer DNFB in a fetal skin dendritic cell line. Journal of Investigative Dermatology 117(4): 1014

Wong, V.Y.; Brooks, D.P. 2001: P38 MAPK is involved in the activation of the caspase cascade in okadaic acid-induced renal cell apoptosis. FASEB Journal 15(4): A80

Takenobu, H.; Umata, T.; Hirata, M.; Mekada, E. 2001: P38 MAPK mediated ectodomain shedding-cascades of proHB-EGF. Cell Structure and Function 26(5): 485

Ballard Croft, C.; Kristo, G.; Yoshimura, Y.; Reid, E.; Keith, B.; Mentzer, R.J.; Lasley, R. 2004: P38 MAPK mediates acute adenosine preconditioning in the adult rat myocardium. FASEB Journal 18(4-5): Abstract 213

Feifel, E.; Taylor, L.; Obexer, P.; Tang, A.; Wei, Y.; Schramek, H.; Curthoys, N.P.; Gstraunthaler, G. 2001: P38 MAPK mediates the acid-induced transcription of PEPCK in LLC-PK1-FBPase+ cells. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 48A

Paliga, A.J.M.; Andrassy, J.C.; Natale, D.R.C.; Watson, A.J. 2003: P38 MAPK modulates cell polarity and trophoblast outgrowth during early murine development. Biology of Reproduction 68(Suppl 1): 337-338

Clark, A.R.; Lasa, M.; Saklatvala, J. 1999: P38 MAPK regulates pro-inflammatory mRNA stability via MAPKAPK2. Cytokine 11(11): 939

Martín-Blanco, E. 2000: P38 MAPK signalling cascades: ancient roles and new functions. Bioessays: News and Reviews in Molecular Cellular and Developmental Biology 22(7): 637-645

Herlaar, E.; Brown, Z. 1999: P38 MAPK signalling cascades in inflammatory disease. Molecular Medicine Today 5(10): 439-447

Bhat, N.; Zhang, P.; Hogan, E.; Feinstein, D. 1999: P38 MAPK signals transcriptional activation of iNOS in glia. Society for Neuroscience Abstracts 25(1-2): 1764

Weinbrenner, C.; Sarvary, L.; Rothe, M.; Strasser, R.H. 2002: P38 MAPK-activation during the infarct-inducing ischemia is essential for the protection of ischemic preconditioning. Circulation 106(19): II193

See, F.C.; Tzanidis, A.; Krum, H. 2002: P38 MAPK-mediated fibrosis following myocardial infarction is regulated by connective tissue growth factor. Circulation 106(19): II267

Sangerman, J.; Ofori Acquah, S.F.; Pace, B.S. 2003: P38 MAPK-mediated gamma globin induction involves altered DNA-protein interactions in an upstream promoter element. Blood 102(11): 515a

Takahashi, N. 2003: P38 MAPK-mediated signals are crucially involved in osteoclast differentiation. Journal of Pharmacological Sciences 91(Suppl I): 43P

Chouinard, N.; Huot, J.; Rouabhia, M. 2000: P38 Mitogen-Activated Protein kinase activation by UV rays protects human keratinocytes against cell death. Proceedings of the American Association for Cancer Research Annual Meeting 41: 708

Bradham, C.; Mcclay, D. 2001: P38 activity is required for embryonic skeletal patterning in the sea urchin. Development Growth and Differentiation 43(Suppl): S35

Schafer, P.H.; Wadsworth, S.A.; Siekierka, J.J. 1999: P38 alpha mitogen-activated protein kinase is activated by CD28-mediated signaling and is required for IL-4 production by human Th2 effector cells. FASEB Journal 13(7): A1473

Bulavin, D.V.; Amundson, S.A.; Fornace, A.J. 2002: P38 and Chk1 kinases: different conductors for the G(2)/M checkpoint symphony. Current Opinion in Genetics and Development 12(1): 92-97

Randle, J.C.R.; Kauffman, R.S. 2001: P38 and ICE/caspase-1 inhibitors for the treatment of inflammatory diseases. Inflammation Research 50(Suppl 3): S149

Tourian, L.J.; Coimbatore, B. 2003: P38 and JNK inhibit Fas-mediated caspase-8 activation but differentially regulate type II apoptotic signaling in Jurkat T lymphocytes. Molecular and Cellular Proteomics 2(9): 712

Conrad, P.W.; Beitner Johnson, D.; Millhorn, D.E. 1999: P38 and p38gamma activation by hypoxia Role in hypoxia-induced proliferation and modulation by the D2 receptor. FASEB Journal 13(5 Part 2): A1091

Lim, M.Y.; Wang, H.; Kapoun, A.M.; O'young, G.; Higgins, L.S.; Protter, A.A. 2003: P38 inhibition attenuates pro-inflammatory activity of C-reactive protein in human peripheral blood monocytes. Circulation 108(17): IV41

Chao, J.I.; Yang, J.L. 2000: P38 kinase and ERK are involved oppositely in cadmium-induced genotoxicity and mitotic arrest. Proceedings of the American Association for Cancer Research Annual Meeting 41: 60

Zayzafoon, M.; Mccabe, L.R. 2001: P38 kinase and its downstream target ATF-2 are involved in the osteoblast osmotic response to elevated extracellular glucose. Journal of Bone and Mineral Research 16(Suppl 1): S374

Bulavin, D.; Higashimoto, Y.; Saito, S.'ichi; Appella, E.; Fornace, A. 2002: P38 kinase as a tumor suppressor. Proceedings of the American Association for Cancer Research Annual Meeting 43: 153

Portanova, J.; Anderson, G.; Mnich, S.; Sagartz, J.; Devraj, R. 2000: P38 kinase inhibitor suppresses inflammation mediated bone loss in rat streptococcal cell wall arthritis. Scandinavian Journal of Immunology 51(Suppl 1): 84

Kintscher, U.; Goetze, S.; Stawowy, P.; Bruemmer, D.; Graf, K.; Law, R.E. 2002: P38 kinase negatively regulates angiotensin II-mediated effects on cell cycle molecules in human coronary smooth muscle cells. Circulation 106(19): II157

Ko, C.B.; Jung, B.H.; Park, R. 2002: P38 kinase regulates phosphorylation and transactivation of p53 in benzo pyrene-mediated apoptosis of Hepa1c1c7 cells. Proceedings of the American Association for Cancer Research Annual Meeting 43: 872

Song, G.Y.; Chung, C.S.; Jarrar, D.; Chaudry, I.H.; Ayala, A. 1999: P38 map kinase activation contributes to macrophage immune dysfunction in sepsis. FASEB Journal 13(5 Part 2): A1152

Chevalier, D.; Allen, B.G. 1999: P38 map kinase attenuates phorbol ester-mediated activation of the ERK map kinase cascade in adult rat ventricular myocytes. Biophysical Journal 76(1 Part 2): A294

Gukovsky, I.; Blinman, T.A.; Mouria, M.; Zaninovic, V.; Livingston, E.; Pandol, S.J.; Gukovskaya, A.S. 2000: P38 map kinase is a key regulator of cytokine and chemokine expression in pancreatic acinar cells. Gastroenterology 118(4 Suppl 2 Pt 1): A157

Hawkins, J.; Zheng, S.; Frantz, B.; LoGrasso, P. 2000: P38 map kinase substrate specificity differs greatly for protein and peptide substrates. Archives of Biochemistry and Biophysics 382(2): 310-313

Abbas, S.; Abu Amer, Y. 2002: P38 mediates RANKL-induced NF-kappaB activation and osteoclastogenesis. Journal of Bone and Mineral Research 17(Suppl 1): S457

Bakin, A.V.; Rinehart, C.C.; Arteaga, C.L. 2002: P38 mitogen activated protein kinase is required for TGFbeta-mediated fibroblastic transition and cell migration. Proceedings of the American Association for Cancer Research Annual Meeting 43: 153

Tadlock, L.; Patel, T. 2000: P38 mitogen activated protein kinase modulates chemosensitivity of malignant cholangiocytes. Gastroenterology 118(4 Suppl 2 Pt 1): AASLD A101

Tyrberg, B.; De La Tour, D. Dufayet; Yoo, S.J.; Itkin Ansari, P.; Levine, F. 2001: P38 mitogen activated protein kinase signalling is required for human beta-cell differentiation. Diabetologia 44(Suppl 1): A 71

D.J.nge, H.W.; Dekkers, D.H.W.; Houtsmuller, A.B.; Lamers, J.M.J. 1999: P38 mitogen-activated kinase activation precedes cyclic stretch and endothelin induced hypertrophy in cardiomyocytes. Journal of Molecular and Cellular Cardiology 31(6): A69

Gysembergh, A.; Kloner, R.A.; Przyklenk, K. 2000: P38 mitogen-activated protein kinase activity is not increased in preconditioned versus control rabbit heart. Circulation 102(18): 2; 211

Hida, M.; Fujita, H.; Omori, S.; Awazu, M. 2001: P38 mitogen-activated protein kinase and extracellular signal-regulated kinase are required for basic fibroblast growth factor -induced DNA synthesis and migration in metanephric mesenchymal cells. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 520A

Henry, J.R.; Cavender, D.E.; Wadsworth, S.A. 1999: P38 mitogen-activated protein kinase as a target for drug discovery. Drugs of the Future 24(12): 1345-1354

Komers, R.; Lindsley, J.L.; Oyama, T.T.; Anderson, S. 2003: P38 mitogen-activated protein kinase expression and activity in diabetic renal cortex Role of metabolic control. Journal of the American Society of Nephrology 14(Abstracts Issue): 129A

See, F.; Tzanidis, A.; Krum, H. 2003: P38 mitogen-activated protein kinase inhibition prevents early adverse ventricular remodelling in the immediate post-myocardial infarction setting. European Heart Journal 24(Abstract Suppl): 26

Mizokoshi, A.; Tsuda, M.; Shigemoto Mogami, Y.; Koizumi, S.; Inoue, K. 2003: P38 mitogen-activated protein kinase inhibitor SB203580 attenuate the mechanical allodynia in neuropathic pain model. Journal of Pharmacological Sciences 91(Suppl I): 187P

Lee, J.C.; Kassis, S.; Kumar, S.; Badger, A.; Adams, J.L. 1999: P38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials. Pharmacology and Therapeutics 82(2-3): 389-397

Tsiani, E.; Fantus, I.G.; Whiteside, C.I. 1999: P38 mitogen-activated protein kinase is activated by high glucose. Diabetes 48(Suppl 1): A68

Mizokoshi, A.; Tsuda, M.; Shigemoto Mogami, Y.; Koizumi, S.; Inoue, K. 2002: P38 mitogen-activated protein kinase is activated in the spinal microglia of neuropathic pain model. Japanese Journal of Pharmacology 88(Suppl 1): 82P

Ogihara, T.; Watada, H.; Kannno, R.; Nomiyama, T.; Tanaka, Y.; German, M.; Kojima, I.; Kawamori, R. 2003: P38 mitogen-activated protein kinase is involved in activin A mediated expression of pro-endocrine gene neurogenin3 in AR42J-B13 cells. Diabetes 52(Suppl 1): A366

Zhang, S.L.; To, C.; Chen, X.; Filep, J.G.; Tang, S.S.; Ingelfinger, J.R.; Chan, J.S.D. 1999: P38 mitogen-activated protein kinase is involved in angiotensinogen gene expression stimulated by high levels of glucose in immortalized rat proximal tubular cells. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 466A

Zhuang, S.; Schnellmann, R.G. 2004: P38 mitogen-activated protein kinase mediates transactivation of epidermal growth factor receptor by oxidative stress in renal epithelial cells. FASEB Journal 18(4-5): Abstract 400

Jung, Y.D.; Shin, B.A.; Kim, H.R.; Ahn, B.W.; Cho, C.K.; Ellis, L.M. 2002: P38 mitogen-activated protein kinase pathway is involved in urokinase plasminogen activator expression and matrix invasiveness in gastric cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting 43: 9

Takano, T.; Aoudjit, L.; Stanciu, M.; Lemay, S. 2002: P38 mitogen-activated protein kinase protects glomerular epithelial cells from complement-mediated cell injury. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 499A

Denkert, C.; Siegert, A.; Leclere, A.; Turzynski, A.; Hauptmann, S. 2000: P38 mitogen-activated protein kinase regulates MMP-2 expression and invasion of malignant melanoma cells. Proceedings of the American Association for Cancer Research Annual Meeting 41: 870

Yamagishi, S.; Yamada, M.; Ishikawa, Y.; Ikeuchi, T.; Hatanaka, H. 2000: P38 mitogen-activated protein kinase regulates low potassium-induced apoptosis in cultured cerebellar granule neurons. Neuroscience Research Suppl (24): S142

Quah, A.; Johnson, E.; Dunlop, M. 2000: P38 mitogen-activated protein kinase response to oxidative stress in two smooth muscle cell types. Journal of Submicroscopic Cytology and Pathology 32(3): 349

See, F.; Tzanidis, A.; Krum, H. 2003: P38 mitogen-activated protein kinase-mediated fibrosis following myocardial infarction is regulated by connective tissue growth factor. European Heart Journal 24(Abstract Suppl): 554

Stanton, L.; Sabari, S.; Beier, F. 2002: P38 mitogen-activated protein kinases in chondrocyte differentiation. Journal of Bone and Mineral Research 17(Suppl 1): S402

Kim, A.L.; Zhu, Y.; Bickers, D.R.; Athar, M. 2003: P38 mitogen-activated protein kinases mediate ultraviolet B -induced COX-2 expression and inflammation in the skin of SKH-1 hairless mice. Journal of Investigative Dermatology 121(1): 0769

Natale, D.R.C.; Watson, A.J. 2001: P38 related/activated kinase translocates from nuclear to peri-nuclear regions just prior to blastocyst formation in the mouse and cow. Biology of Reproduction 64(Suppl 1): 279

Ardeshna, K.M.; Addison, I.E.; Pizzey, A.R.; Linch, D.C.; Devereux, S.; Khwaja, A. 1999: P38 stress-activated protein kinase activity is required for the lipopolysaccharide-induced maturation of monocyte-derived dendritic cells. British Journal of Haematology 105(Suppl 1): 33

Khurana, A.; Goel, H.L.; Dey, C.S. 2001: P38, a subtype of mitogen activated protein kinase is essential for the differentiation of skeletal muscle cells. FASEB Journal 15(5): A1162

Burt, D.; Gruden, G.; Thomas, S.; Viberti, G.; Gnudi, L. 2002: P38-MAPK mediates hexosamine-induced TGFbeta1 mRNA expression in human mesangial cells. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 315A-316A

Bourgeade, M.F.; Schrantzs, N.; Mouhamad, S.; Leca, G.; Vazquez, A. 2001: P38-mediated regulation of a FADD-independent pathway leading to caspase-8 activation during TGFbeta-induced apoptosis in the human Burkitt lymphoma B cells BL41. Biology of the Cell 93(1-2): 117

Burt, D.; Gruden, G.; Thomas, S.M.; Tutt, P.; Viberti, G.; Gnudi, L. 2002: P38-mitogen activated protein kinase mediates hexosamine-induced TGFbeta1 mRNA expression in human mesangial cells. Diabetologia 45(Suppl 2): A 75

Oda, A.; Fujita, H.; Nishio, M.; Koike, T.; Sawada, K. 2001: P38MAP kinase is proapoptotic in human primary erythroid cells. Experimental Hematology 29(8 Suppl 1): 46

Zhu, S.; Lou, N.; Zheng, X.; Li, Y.; Liu, X.; Yu, X. 2003: P38MAPK expression and activation in renal tubulointerstitial fibrosis in rat model of unilateral ureteral obstruction Role of angiotensin II. Journal of the American Society of Nephrology 14(Abstracts Issue): 121A

Mehta, K.D.; Singh, R.P. 2003: P38MAPK inhibitor and uses thereof. Official Gazette of the United States Patent and Trademark Office Patents 1273(1)

Ignatoski, K.M.W.; Grewal, N.K.; Ethier, S.P. 2003: P38MAPK-activated AKT in erbB-2-overexpressing cells acts as an EGF-independent survival signal. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1186

Azuma, N.; Kito, H.; Ikeda, M.; Akasaka, N.; Sasajima, T.; Sumpio, B.E. 2000: P38alpha MAP kinase regulates morphological changes induced by fluid shear stress. FASEB Journal 14(4): A450

Nishida, K.; Yamaguchi, O.; Hikoso, S.; Hori, M.; Otsu, K. 2003: P38alpha mitogen-activated protein kinase plays a critical role in cardiomyocyte survival in response to pressure overload. Circulation 108(17): IV145

Ho, R.; Alcazar, O.; Fujii, N.; Hirshman, M.; Goodyear, L. 2003: P38gamma MAPK regulation of glucose uptake in L6 myotubes and mouse skeletal muscle. Diabetes 52(Suppl 1): A279

Haarer, M.; Polich, J. 2000: P3A assessment of tobacco smoking in chippers and smokers. Psychophysiology 37(Suppl 1): S45

Hibi, K.; Trink, B.; Yamaguchi, K.; Jen, J.; Sidransky, D. 1999: P40 gen amplification in squamous cell lung carcinoma. Proceedings of the American Association for Cancer Research Annual Meeting 40: 376

Sidransky, D.; Jen, J.; Trink, B.; Ratovitski, E.A. 2002: P40 protein acts as an oncogene. Official Gazette of the United States Patent and Trademark Office Patents 1264(1)

Ratovitski, E.; Trink, B.; Resto, V.; Rocco, J.; Sidransky, D. 1999: P40-binding proteins. Proceedings of the American Association for Cancer Research Annual Meeting 40: 103

Bouin, A.P.; Grandvaux, N.; Vignais, P.V.; Fuchs, A. 1999: P40phox is phosphorylated on T154 and S315 by a protein kinase C-type kinase during NADPH oxidase activation. European Journal of Clinical Investigation 29(Suppl 1): 41

Morita, A.; Suzuki, N.; Enomoto, A.; Matsumoto, Y. 2000: P41 is a cleavage product from oncoprotein SETbeta by caspase in radiation-induced MOLT-4 cell death. Journal of Radiation Research 41(4): 414

D.B.er, R.A.; Pinto, Y.M.; Suurmeijer, A.J.H.; Van Veldhuisen, D.J.; Flesch, M.; Van Gilst, W.H.; Boomsma, F. 2001: P42/44 member of the mitogen-activated protein kinase family is activated in left ventricular hypertrophy before the transition towards heart failure in homozygous REN2 rats. European Heart Journal 22(Abstract Suppl): 680

Klingenberg, D.; Guenduez, D.; Piper, H.M.; Noll, T. 2002: P42/44 mitogen activated kinase controls phosphorylation of myosin light chains induced by extracellular ATP in endothelial cells. Circulation 106(19): II150

Singh, K.; Communal, C.; Pimental, D.R.; Pligavko, C.A.; Colucci, W.S. 1999: P42/44 mitogen-activated protein kinase and reactive oxygen species mediate angiotensin II-stimulated osteopontin expression in cardiac microvascular endothelial cells. Circulation 100(18): 1; 430

Yoshino, J.; Yoshida, T.; Monkawa, T.; Hayashi, M.; Saruta, T. 2002: P42/44 mitogen-activated protein kinase is required for calcitonin-induced 25-hydroxyvitamin D 1alpha-hydroxylase gene expression. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 195A-196A

Longuet, C.; Bataille, D.; Dalle, S. 2003: P42/p44 MAP kinases activation is required for insulin secretion in response to physiological glucose concentrations in the MIN6 pancreatic beta cell line. Diabetes 52(Suppl 1): A373

Walker, D.H.; Mcbride, J.W. 2002: P43 antigen for the immunodiagnosis of canine ehrlichiosis and uses thereof. Official Gazette of the United States Patent and Trademark Office Patents 1256(2)

Maccallum, A.; Everest, P. 2003: P44 and p42 MAP kinase enzyme activity is up regulated in Caco-2 cells cultured with Campylobacter jejuni. IJMM International Journal of Medical Microbiology 293(Suppl 35): 68

Wolf, G.; Hannken, T.; Zahner, G.; Shankland, S.J.; Stahl, R.A.K. 2001: P44/42 MAP kinase directly phosphorylates the CDK-inhibitor p27KIP1 Role in hypertrophy. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 623A-624A

Sassa, Y.; Hata, Y.; Murata, T.; Ishibashi, T.; Inomata, H. 2000: P44/p42 MAP kinase and transcription factor Egr-1 mediate VEGF induced TF expression by retinal capillary endothelial cells. IOVS Investigative Ophthalmology and Visual Science 41(4): S870

Figini, A.; Caimi, T.M.; Lando, G.; Patrosso, M.C.; Mostarda, G.; Marocchia, A.; Baudo, F. 2000: P450 CYP2C9 polymorphism in patients on oral anticoagulant treatment. Haemostasis 30(Suppl 1): 106-107

Tucker, G.T. 2000: P450 enzymes and polymorphism. Journal of Pharmacy and Pharmacology 52(Suppl): 293

Gonzalez, F.J.; Yu, A.; Cheung, C.; Granvil, C.P.; Kupfer, A.; Idle, J.R. 2003: P450 humanized mice Novel animal models for the study of drug and carcinogen metabolism, and the search for endogenous human P450 substrates and functions. Drug Metabolism Reviews 35(Suppl 2): 19

Yu, A.M.; Cheung, C.; Akiyama, T.E.; Granvil, C.P.; Idle, J.R.; Gonzalez, F.J. 2003: P450 humanized mice for the study of xenobiotics. Drug Metabolism Reviews 35(Suppl 2): 31

Granvil, C.P.; Gonzalez, F.J. 2004: P450 humanized mice for the study of xenobiotics CYP3A4 as a paradigm. FASEB Journal 18(4-5): Abstract 793

Chatterjee, P.; Havea, R.N.; Franklin, M.R. 2003: P450 inhibition by methylenedioxyphenyl compounds present in goldenseal. Toxicological Sciences 72(S-1): 320

Pirmohamed, M. 2003: P450 polymorphisms and adverse drug reactions. Toxicology 192(1): 55-56, October 1st

Monaghan, J.E.; Stratford, I.J. 2000: P450 reductase Effect on cisplatin/tirapazamine synergy. Proceedings of the American Association for Cancer Research Annual Meeting 41: 765

Scarborough, P.E.; Ma, J.; Qu, W.; Zeldin, D.C. 1999: P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metabolism Reviews 31(1): 205-234

Reilly, C.A.; Yost, G.S. 2003: P450-mediated metabolism of capsaicin decreases cytotoxicity to lung and liver cells. Toxicological Sciences 72(S-1): 336-337

Yasuda, S.U.; Soukhova, N. 2003: P450-mediated metabolism of chlorpheniramine in vitro. Clinical Pharmacology and Therapeutics 73(2): P84

Inouye, L.S.; Mcfarland, V.A.; Ang, C.Y.w 2001: P450RGS A cell-based assay for determining dioxin equivalents in environmental samples. Abstracts of Papers American Chemical Society 221(1-2): BIOT 222

Miller, W.L. 1999: P450c17, adrenarche and the polycystic ovary syndrome. Hormone Research 51(Suppl 2): 2

Miller, W.L. 1999: P450c17-The qualitative regulator of steroidogenesis. Handwerger, S Contemporary Endocrinology; Molecular and cellular pediatric endocrinology 139-152

Touyz, R.M.; Yao, G.; He, Y.; Schiffrin, E.L. 2004: P47phox association with actin is critical for site-directed activation of NAD H oxidase by Ang II in human vascular smooth muscle cells. Hypertension 43(6): 1347

Summerfelt, A.; Gold, J.; Buchanan, R.W. 1999: P50 and memory performance in schizophrenia. Society for Neuroscience Abstracts 25(1-2): 572

Bonnet Brilhault, F.; Raux, G.; Louchart, S.; Houy, E.; Petit, M.; Frebourg, T.; Thibaut, F.; Campion, D. 2000: P50 ratio and the -2bp deletion of the alpha7 nicotinic acetylcholine receptor. American Journal of Medical Genetics 96(4): 527-528

Myles Worsley, M.; Ord, L.; Blailes, F.; Freedman, R. 2003: P50 sensory gating in high risk adolescents from Palau, Micronesia. American Journal of Medical Genetics 122B(1): 85-86

Jiang, Z.; Xue, Y.D.; Fanger, G.; Pihan, G.; Reed, S.; Woda, B.; Xu, J.C. 2001: P504S A good diagnostic marker for prostate carcinoma. Laboratory Investigation 81(1): 111A

Jiang, Z.; Wu, C.L.; Woda, B.A.; Dresser, K.; Fanger, G.R.; Xu, J.; Rock, K.L.; Yang, X. 2002: P504S A good diagnostic marker for small focus of prostatic adenocarcinoma on needle biopsy. Laboratory Investigation 82(1): 166A

Gupta, N.; De Peralta Venturina, M.; Gown, A.; Beach, R.; Salles, P.; Yaziji, H.; Amin, M.B. 2003: P504S antibody expression in putative precursor lesions of prostate carcinoma - high grade prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Modern Pathology 16(1): 152A

Yang, X.J.; Wu, C.L.; Amin, M.B.; Young, R.; Fanger, G.; Jiang, Z. 2002: P504S in diagnosis of prostate cancer A multi-institutional analysis. Laboratory Investigation 82(1): 187A

Ikawa, Y.; Katoh, I.; Okada, Y.; Osada, M.; Kurata, S.I.hi 2002: P51 -encoded, secondary trans-activator p51B is also stabilized by genotoxic stress, whose mechanism may not involve MDM2. Proceedings of the American Association for Cancer Research Annual Meeting 43: 985

Lee, M.S.; Igawa, T.; Zhang, X.Q.; Lin, F.F.; Lin, M.F. 2001: P52Shc is involved in androgen-stimulated proliferation of human prostate cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting 42: 546

Jiang, Z.; Gokden, M.; Banner, B.; Liu, Y.; Savas, L.; Woda, B.; Ayala, A. 2000: P53 A good diagnostic marker for intratubular germ cell neoplasia. Laboratory Investigation 80(1): 103A

Laframboise, S.; Chapman, W.; Andrulis, I. 1999: P53 A possible predictor of response to taxol-based chemotherapy in advanced epithelial ovarian cancers. Gynecologic Oncology 72(3): 507

Offringa, R.; Vierboom, M.P.; van der Burg, S.H.; Erdile, L.; Melief, C.J. 2000: P53: a potential target antigen for immunotherapy of cancer. Annals of the new York Academy of Sciences 910: 223-233; Discussion: 233-236

Zhao, X.; Wang, L.D.; Yang, G.Y.; Cai, Y.C.; Yang, C.S. 1999: P53 Alterations in primary and metastatic esophageal cancers in a high incidence area of esophageal cancer in northern China. Proceedings of the American Association for Cancer Research Annual Meeting 40: 278

Shaham, J.; Melzer, A.; Kaufman, Z.; Rashkovsky, M.; Ribak, J. 1999: P53 And sister chromatid exchange in relation to exposure to pesticides00. Proceedings of the American Association for Cancer Research Annual Meeting 40: 508

Wynford Thomas, D.; Kipling, D. 2001: P53 At the cross-roads of senescence and cancer. Mutagenesis 16(6): 559

Saville, M.K.; Lain, S.; Xirodimas, D.; Lane, D.P. 2002: P53 Basic concepts for cytologists. Acta Cytologica 46(1 Suppl): 225

Giannoudis, A.; Southern, S.A.; Herrington, C.S. 1999: P53 Codon 72 polymorphism and HPV infection in low and high grade squamous intraepithelial lesions of the cervix and invasive cancer. Proceedings of the American Association for Cancer Research Annual Meeting 40: 444

Fan, R.; Wu, M.T.; Wain, J.C.; Kelsey, K.T.; Wiencke, J.K.; Christiani, D.C. 1999: P53 Codon 72 polymorphism and lung cancer. Proceedings of the American Association for Cancer Research Annual Meeting 40: 248

Brat, D.J.; Pecot, M.J.; Devi, N.S.; Van Meir, E.G. 2003: P53 Differentially regulates hypoxia-inducible pro-angiogenic cytokines in malignant glioma. FASEB Journal 17(4-5): Abstract 406

Sabrina, S.; Giulia, F.; Giulia, R.M.; Ada, S.; Moshe, O.; Blandino, G. 2001: P53 Family interactions What implications in human carcinogenesis?. International Journal of Molecular Medicine 8(Suppl 1): S48

Selivanova, G. 2004: P53: fighting cancer. Current Cancer Drug Targets 4(5): 385-402

Jacob, T.; Ascher, E.; Scheinman, M.; Hingorani, A.; Gade, P.; Fodera, M.; Tunio, A.; Seth, P. 1999: P53 Gene transfer to the injured rat carotid artery, its role in reducing neointimal formation and apoptosis. FASEB Journal 13(4 Part 1): A129

Suh, Y.H.; Chae, H.S.; Kim, H.S.; Seo, J.H.; Park, C.H.; Jeong, S.J.; Kim, S.S. 1999: P53 Modulate ceramide induced apoptosis in SK-N-SH cell. Society for Neuroscience Abstracts 25(1-2): 570

Isacson, C.; Kurman, R.J.; Ellenson, L.H. 1999: P53 Mutation analyses support the use of broad histopathologic criteria for the diagnosis of uterine serous carcinoma. Modern Pathology 12(1): 118A

Vriesema, J.; Van Rhijn, B.; Hessels, D.; Van Der Poel, H.; Witjes, F.; Debruyne, F.; Schalken, J. 1999: P53 Mutation analysis and DNA ploidy in bladder wash material. European Urology 36(5): 503

Baez, A.; Vega, W.; Cruz, L.; Enamorado, I.; Salgado, N. 2001: P53 Polymorphism and HPV16 infection in a Puerto Rican population with head and neck squamous cell carcinoma. Proceedings of the American Association for Cancer Research Annual Meeting 42: 751

Done, S.J.; Arneson, N.C.R.; Ozhelik, H.; Inoue, M.; Duggan, M.A. 1999: P53 Polymorphism in HPV related cervical carcinoma Relationship with time to invasion. Modern Pathology 12(1): 115A

Sun, D.; Park, J.; Crum, C.P. 1999: P53 Polymorphisms Do they really influence cervical cancer risk?. Modern Pathology 12(1): 125A

Nakamura, S.; Roth, J.A.; Mukhopadhyay, T. 2001: P53 Requires intact C terminus for G2 delay. Proceedings of the American Association for Cancer Research Annual Meeting 42: 734

Hermanns, M.; Rohrmann, D.; Richter, A.P.; Buettner, R.; Malone, M.; Jakse, G. 2004: P53 a prognostic marker in Wilms Tumor. Journal of Urology 171(4 Suppl): 148-149

Haruma, K.; Ito, M.; Kohmoto, K.; Kamada, T.; Kitadai, Y.; Yasui, W.; Tahara, E.; Kajiyama, G. 1999: P53 abnormality is not related to atrophic gastritis-gastric cancer pathway induced by Helicobacter pylori infection Study of young Japanese patients. Gastroenterology 116(4 Part 2): A418-A419

Shibata, A.; Longacre, T.A.; Garcia, M.I.; Puligandia, B.; Parsonnet, J.; Davis, R.E.; Habel, L.A. 1999: P53 abnormally in stomach cancer by histological subtype. Proceedings of the American Association for Cancer Research Annual Meeting 40: 243

Jowsey, P.A.; Farnie, G.; Durkacz, B.; Lunec, J. 2002: P53 accumulation and p53 mediated transcriptional transactivation in response to ionizing radiation is independent of poly polymerase-1. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1138

Regula, K.M.; Kirshenbaum, L.A. 2001: P53 activates apoptosis of ventricular myocytes independent of de novo gene transcription. Journal of Molecular and Cellular Cardiology 33(6): A100

Schwartz, R.; Zan Bar, I. 2001: P53 activations abnormalities in CVID patients. FASEB Journal 15(5): A1013

Branda, R.F.; O'neill, J.P.; Brooks, E.M.; Trombley, L.M.; Nicklas, J.A. 2000: P53 activity modulates the effect of folate deficiency on genetic damage caused by alkylating agents in human lymphoblastoid cells. Proceedings of the American Association for Cancer Research Annual Meeting 41: 69

Keyhani, A.; Liu, B.; Dinney, C.P.N.; Pagliaro, L.C. 1999: P53 adenovirus-mediated gene transfer in bladder cancer. Proceedings of the American Association for Cancer Research Annual Meeting 40: 527

Mahvash, M.; Kueppers, V.; Beckmann, M.W.; Bender, H.G.; Niederacher, D. 2001: P53 allele-specific predisposition in human papillomavirus-associated cervical cancer. Journal of Cancer Research and Clinical Oncology 127(Suppl 1): S22

A.M.ghrabi, J.; Vorobyova, L.; Zielenska, M.; Jewett, M.; Chapman, W.; Squire, J. 2002: P53 alteration and chromosomal instability in prostatic high grade intraepithelial neoplasia and concurrent carcinoma Analysis by immunohistochemistry, interphase in situ hybridization, and sequencing of Laser captured microdissected specimens. Laboratory Investigation 82(1): 151A

Boyapati, A.; Kanbe, E.; Zhang, D.-E. 2004: P53 alterations in myeloid leukemia. Acta Haematologica 111(1-2): 100-106

Vargas, S.O.; Korpershoek, E.; Kozakewich, H.P.W.; De Krijger, R.R. 2004: P53 analysis in congenital cystic adenomatoid malformation and pleuropulmonary blastoma. Modern Pathology 17(2): 274

Junker, K.; Utting, M.; Werner, W.; Schubert, J.; Dahse, R. 2002: P53 analysis in urine and blood A new powerful diagnostic tool for bladder cancer?. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1139-1140

Gocke, C.D.; Benko, F.A.; Kopreski, M.S.; Mcgarrity, T.J. 2000: P53 and APC mutations are detectable in the plasma and serum of patients with colorectal cancer or adenomas. Anker, Philippe Author, Stroun, Maurice Author Annals of the New York Academy of Sciences; Circulating nucleic acids in plasma or serum 44-50

Hussein, M.R.; Midtling, A.K.; Wood, G.S. 2002: P53 and Bcl2 expression in radial growth phase Wistar melanoma cell lines following ultraviolet irradiation. Journal of Investigative Dermatology 119(1): 222

Langhanki, L.; Tannapfel, A.; Busse, C.; Hauss, J.; Wittekind, C. 2002: P53 and CDKN2a inactivation in primary angiosarcoma of the liver. Pathology Research and Practice 198(3): 185

Saifudeen, Zubaida; Dipp, Susana; El Dahr, Samir S. 1999: P53 and CREB cooperativity activates bradykinin B2 receptor gene transcription in renal epithelial cells. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 410A

Capuzzi, D.M.; Mccue, P.; Webner, D.; Kovatich, A.; Barusevicius, A.; Huebner, K. 1999: P53 and FHIT protein immunohistochemistry in primary gastric adenocarcinoma. Modern Pathology 12(1): 72A

Chau, L.Y.; Lee, T.S. 2000: P53 and Fas/Fas ligand dependent pathways are involved in oxidized low-density lipoprotein -induced apoptosis in vascular smooth muscle cells. FASEB Journal 14(4): A121

Maru, D.; Middleton, L.P.; Wang, S.; Valero, V.; Sahin, A. 2003: P53 and Her2 neu expression in breast carcinoma occuring in young women. Modern Pathology 16(1): 40A

Schmitt, C.A.; Yang, M.; Fridman, J.S.; Baranov, E.; Hoffman, R.M.; Lowe, S.W. 2002: P53 and INK4a/ARF genes cooperate in drug-induced apoptosis and senescence in vivo. Proceedings of the American Association for Cancer Research Annual Meeting 43: 834

Heinzlmann, M.; Neynaber, S.; Petrovitsch, M.; Heldwein, W.; Loeschke, K.; Folwaczny, C. 2000: P53 and K-ras gene in colonic lavage and p53 autoantibodies in serum in patients with colonic adenomas. Gastroenterology 118(4 Suppl 2 Pt 1): A260

Couture, C.; Murry, D.; Allard, J.; Fortin, A.; Tetu, B. 2000: P53 and Ki-67 as factors of radioresistance and prognosis in squamous cell carcinoma of head and neck. Laboratory Investigation 80(3): 136A

Batinac, T.; Zamolo, G.; Jonjic, N.; Gruber, F.; Krasevic, M. 2003: P53 and Ki-67 in non-neoplastic and neoplastic proliferative skin diseases. Virchows Archiv 443(3): 373

Kodama, M.; Fujioka, T.; Murakami, K.; Sato, R.; Okimoto, T.; Oda, T.; Kubota, T.; Nasu, M. 2000: P53 and MDM2 expression in gastric mucosa with Helicobacter pylori infection. Gastroenterology 118(4 Suppl 2 Pt 2): AGA A1393

Di Vizio, D.; Insabato, L.; Salerno, G.; Mezza, E.; Staibano, S.; Mansueto, G.; Mottola, G.; Nardone, M.; Galli, V.; De Rosa, G. 2003: P53 and MIB1 expression in basaloid squamous cell carcinoma of the larynx inversely correlates with p27 expression. Virchows Archiv 443(3): 262-263

Kerbauy, F.R.; Colleoni, G.W.B.; Duarte, L.C.C.; Alves, A.C.; Seixas, M.T.; Aguiar, K.C.C.; Albuquerque, D.M.; Silva, M.R.R. 2002: P53 and P21 Proteins Combined with the International Prognostic Index Can Improve the Prediction of Outcome in Patients with Diffuse Large B-Cell Lymphoma. Blood 100(11): Abstract No. 4693

Whitman, M.; McKeon, F. 2003: P53 and TGF-beta in development: prelude to tumor suppression?. Cell 113(3): 275-276

Fernandez Salas, E.; Sagar, M.; Cheng, C.; Yuspa, S.H.; Weinberg, W.C. 1999: P53 and TNF-alpha regulate a mitochondrial chloride channel protein associated with apoptosis in keratinocytes. Proceedings of the American Association for Cancer Research Annual Meeting 40: 101

Kirkwood, T.B.L. 2002: P53 and ageing: too much of a good thing?. Bioessays: News and Reviews in Molecular Cellular and Developmental Biology 24(7): 577-579

Losi, E.; Molinari, A.M.; Gazzerro, P.; Ortega De Luna, L.; Fera, M.T.; Carbone, M.; Catania, M.R.; Hasty, D.L.; Rossano, F. 2002: P53 and anti-p53 antibodies as possible markers of a switch towards a neoplastic phenotype in patients infected by Helicobacter pylori. Annals of the new York Academy of Sciences 963: 329-331

Nawa, N.; Hongyo, T.; Parida, D.; Rath, G.; Nakamoto, N.; Nagahara, R.; Nomura, T. 2003: P53 and bak mutations in oral cancers associated with betel quid chewing in India. Journal of Radiation Research 44(4): 450-451

Rossi, S.; Grandi, E.; Martinello, R.; Cavazzini, L. 1999: P53 and bcl-2 expression and chemoresistance in ovarian carcinomas. Virchows Archiv 435(3): 350

Quintero, A.; Correa, I.; Salazar, A.M.; Garcia Carranca, A.; Cerbon, M.A. 2001: P53 and bcl-2 expression in human cervix cancer cell lines after estradiol treatment. Proceedings of the American Association for Cancer Research Annual Meeting 42: 240

Fujii, S.; Eichhorn, J.H.; Bell, D.A. 2000: P53 and bcl-2 expression in ovarian micropapillary serous tumors. Laboratory Investigation 80(3): 124A

Fisseler Eckhoff, A.; Klaus, C.; Beres, C. 2001: P53 and bcl-2 expression in typical and atypical carcinoid tumors of the lung. Pathology Research and Practice 197(5): 312

Bell, D.A.; Mok, S. 2001: P53 and c-erbB2 overexpression in microscopic ovarian carcinomas. Laboratory Investigation 81(1): 133A

Szumiel, B. 2000: P53 and cell signalling. Radiotherapy and Oncology 56(Suppl 1): S54

E.Deiry, W.S. 1999: P53 and drug sensitivity. Proceedings of the American Association for Cancer Research Annual Meeting 40: 771-772

Sonoda, Y.kio; Saigo, Patricia, E.; Boyd, Jeff 1999: P53 and genetic susceptibility to cervix cancer. Gynecologic Oncology 72(3): 461-462

Roehrich, K.; Vieth, M.; Stolte, M.; Tannapfel, A. 2003: P53 and homologues in Barretts adenocarcinoma and precursor lesions The delta-N isoform of p63 a predictor for malignant potential?. Pathology Research and Practice 199(4): 231

Langhanki, L.; Weber, A.; Gerstner, A.; Bootz, F.; Wittekind, C.; Tannapfel, A. 2003: P53 and homologues in benign salivary gland tumours The DELTAN isoform of p63 a predictor for malignant potential?. Pathology Research and Practice 199(4): 224-225

Hammond, E.M.; Giaccia, A. 2001: P53 and hypoxia mediated gene repression. Proceedings of the American Association for Cancer Research Annual Meeting 42: 702

Weber, A.; Tannapfel, A.; Bellmann, U.; Bootz, F.; Wittekind, C. 2001: P53 and its homologues p63 and p73 in primary and secondary squamous cell carcinomas of the head and neck. Virchows Archiv 439(3): 245-246

Botchkarev, V.; Komarova, E.; Siebenhaar, F.; Botchkareva, N.; Sharov, A.; Komarov, P.; Maurer, M.; Gudkov, A.; Gilchrest, B. 2001: P53 and its target genes are essential for chemotherapy-induced hair loss. Journal of Investigative Dermatology 117(2): 428

Deb, D.; Scian, M.; Li, W.; Keiger, J.; Chakraborti, A.S.; Deb, S.P.; Deb, S. 2001: P53 and its tumor-derived mutants Involvement in transcription. International Journal of Molecular Medicine 8(Suppl 1): S75

Glaser, C.; Sumper, A.; Eckert, R.; Millesi, W.; Steiner, G. 1999: P53 and ki67 expression of oral squamous cell carcinomas of patients undergoing neoadjuvant radiochemotherapy. Proceedings of the American Association for Cancer Research Annual Meeting 40: 555

Khan, M. 2002: P53 and matrix metalloproteinases in rheumatoid arthritis: tip of an angiogenic iceberg?. Seminars in Arthritis and Rheumatism 31(5): 287-288

Dworakowska, D.; Jassem, E.; Wiedorn, K.; Dziadziuszko, R.; Goldmann, T.; Kobierska, G.; Skokowski, J.; Bosse, A.; Czestochowska, E.; Jassem, J. 2001: P53 and mdm2 expression in non-small cell lung cancer The lack of prognostic relevance. Pathology Research and Practice 197(5): 333

Reid, B.J. 2001: P53 and neoplastic progression in Barrett's esophagus. American Journal of Gastroenterology 96(5): 1321-1323

Mannweiler, S.; Bcham, A.; Regauer, S. 1999: P53 and p-glycoprotein expression in primary oropharyngeal SCC. Virchows Archiv 435(3): 173

Su, L.; Sai, Y.; Fan, R.; Thurston, S.W.; Miller, D.P.; Xu, L.L.; Wain, J.C.; Lynch, T.J.; Liu, G.; Christiani, D.C. 2002: P53 and p21 polymorphisms alter in vivo mRNA expression of p21. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1021

Yazlovitskaya, E.M.; Dehaan, R.D.; Pelling, J.C.; Persons, D.L. 2000: P53 and p21WAF-1 protein accumulation in cisplatin-sensitive and -resistant ovarian carcinoma cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 41: 623

Morrissey, J.J.; Sato, M.; Klahr, S. 2003: P53 and p63 regulate gene expression during renal fibrosis. Journal of the American Society of Nephrology 14(Abstracts Issue): 19A

Naidu, R.; Kutty, M.K. 2002: P53 and p73 abnormalities in primary breast carcinoma. International Journal of Molecular Medicine 10(Suppl 1): S42

Suliman, M.E.R.; Royds, J.A.; Powell, T.; Timperley, W.R.; Cullen, D.R.; Jones, T.H. 1999: P53 and pituitary tumour volume and invasiveness. Journal of Endocrinology 160(Suppl ): P145

Galipeau, P.C.; Longton, G.M.; Sanchez, C.A.; Kraemer, P.S.; Kissel, H.D.; Ayub, K.; Blount, P.L.; Rabinovitch, P.S.; Reid, B.J. 2003: P53 and ploidy abnormalities in combination are stronger predictors of progression to esophageal adenocarcinoma than either biomarker alone in Barretts esophagus. Cancer Epidemiology Biomarkers and Prevention 12(11 Part 2): 1285s-1286s

Hakin Smith, V.; Battersby, R.D.; Ironside, J.W.; Timperley, W.R.; Royds, J.A. 1999: P53 and progesterone receptor status in meningiomas. British Journal of Cancer 80(Suppl 2): 34

Bodis, S.; Glanzmann, C.; Fabbro, D.; Krek, W.; Pruschy, M. 2000: P53 and radiation A rational step towards radiotherapy tailored to molecular prognostic factors. Radiotherapy and Oncology 56(Suppl 1): S54

Sengupta, P.; Blackhall, F.; Charalambous, C.; Bajaj, V.; Ward, T.; Swindell, R.; Bromley, M.; Shanks, J.; Buckley, C.H.; Reynolds, K.; Mcgown, A.; Jayson, G.C. 1999: P53 and related proteins in ovarian cancer. British Journal of Cancer 80(Suppl 2): 72

Harrison, D. 1999: P53 and the decision to die. Journal of Pathology 189(Suppl): 28A

Albor, A.; Kulesz Martin, M. 2000: P53 and the development of genomic instability Possible role for topoisomerase I interaction. Ehrlich, Melanie DNA alterations in cancer: Genetic and epigenetic changes 409-422

Smith, P.J.; Jones, C.J. 1999: P53 and the integrated response to DNA damage. Smith, Paul Journal Author, Jones, Christopher Journal Author Frontiers in Molecular Biology; DNA Recombination and Repair 203-231

Iversen, P.L. 2002: P53 antisense agent and method. Official Gazette of the United States Patent and Trademark Office Patents 1257(1)

Narayan, A.; Stien, E.; Johnson, M.; Dornfeld, K.J.; Kukuruga, M.A.; Carey, T.E.; Bradford, C.R. 2001: P53 as a moderator of G2/M arrest after gamma-irradiation of head and neck squamous cell carcinomas. Proceedings of the American Association for Cancer Research Annual Meeting 42: 386

Bonnefoi, H.; Movarekhi, S.S.; Pelte, M.F.; Bongard, S.; Iggo, R.; Schaefer, P. 2000: P53 as a potential predictive factor of response to chemotherapy Feasibility of p53 assessment using a molecular biology functional test in yeast from trucut biopsies in breast cancer patients. European Journal of Cancer 36(Suppl 5): S120

Gianni, S.; Cecchetto, A.; Altavilla, G.; Michelotto, M.; Rinaldi, M.; De Giorgio, M.; Fagiuoli, S.; Farinati, F. 2003: P53 as a prognostic predictor in hepatocellular carcinoma. Journal of Hepatology 38(Suppl 2): 96-97

Vize, P.D.; Wallingford, J.B. 2002: P53 as a regulator of cell differentiation. Official Gazette of the United States Patent and Trademark Office Patents 1264(2)

Mantovani, R.; Imbriano, C.; Cocchiarella, F. 2003: P53 as a switch for repression PCAF-mediated acetylation represses G2/M promoters through multiple NF-Y sites. Proceedings of the American Association for Cancer Research Annual Meeting 44: 420

Fojo, T. 2002: P53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer ChemoTherapy 5(5): 209-216

Galatin, P.S.; Bsgler, O.; Abraham, D.J. 2000: P53 as an allosteric system Assays for potential modulators of DNA-binding activity and inhibition by MDM2. Proceedings of the American Association for Cancer Research Annual Meeting 41: 768

Regele, S.; Vogl, F.D.; Kreienberg, R.; Runnebaum, I.B. 2001: P53 autoantibodies in patients with non-metastatic invasive breast cancer can be indicative for the development of relapse. Journal of Cancer Research and Clinical Oncology 127(Suppl 1): S22

Broll, R.; Duchrow, M.; Oevermann, E.; Markert, U.; Windhoevel, U. 2000: P53 autoantibodies in serum of patients with colorectal cancer A valuable tumor marker?. European Surgical Research 32(Suppl 1): 7-8

Krammer, P.; Muller Schilling, M.; Oren, M. 2004: P53 binding areas. Official Gazette of the United States Patent and Trademark Office Patents 1285(1)

Tan, T.; Purcell, T.; Chu, G. 2002: P53 binds and activates the xeroderma pigmentosum p48 gene in humans but not mice. Environmental and Molecular Mutagenesis 39(Suppl 33): 62

Martinez, F.J.; Guo Qing, Z.; Pineyro, A.; Garza Ocanas, L.; Tomei, L.D.; Umansky, S. 1999: P53 caspase independent apoptosis induction by peroxisomicine compound. Proceedings of the American Association for Cancer Research Annual Meeting 40: 580

Banez, L.L.; Gao, C.L.; Xu, L.; Ali, A.; Connelly, R.R.; Mcleod, D.G.; Moul, J.W.; Srivastava, S. 2003: P53 codon 72 Arg single nucleotide polymorphism is associated with prostate cancer. Proceedings of the American Association for Cancer Research Annual Meeting 44: 460-461

Yip, L.; Hwang, S.J.; Strong, L.C.; Lozano, G. 2003: P53 codon 72 polymorphism and cancer risk in Li-Fraumeni syndrome. American Journal of Human Genetics 73(5): 471

Papadakis, E.D.; Soulitzis, N.; Spandidos, D.A. 2002: P53 codon 72 polymorphism and its association with advanced lung cancer. International Journal of Molecular Medicine 10(Suppl 1): S94

Yip, L.; Hwang, S.J.; Strong, L.C.; Lozano, G. 2003: P53 codon 72 polymorphism and phenotype association in Li-Fraumeni syndrome. Proceedings of the American Association for Cancer Research Annual Meeting 44: 106

O'connor, D.P.; Mabruk, M.J.E.M.F.; Leader, M.; Atkins, G.J.; Murphy, G.M.; Kay, E.W. 1999: P53 codon 72 polymorphism and the development of human papilloma virus-associated skin cancer. British Journal of Cancer 80(Suppl 2): 79

Pezeshki, A.; Sari Aslani, F.; Ghaderi, A.; Doroudchi, M. 2003: P53 codon 72 polymorphism in basal cell carcinoma of skin. EJC Suppls 1(5): S181-S182

Fiszer Maliszewska, L.; Wojciechowska, B.; Czernik, J.; Sawicz Birkowska, K.; Kazanowska, B.; Mikolajewska, A.; Godzinski, J.; Rapala, M.; Nowakowska, B.; Nowak, I.; Pochron, B.; Kusnierczyk, P. 2002: P53 codon 72 polymorphism in cancer patients in high-risk groups in Poland. International Journal of Cancer Suppl (13): 185

Sul, J.H.; Zhang, Z.F.; Kurtz, R.C. 2001: P53 codon 72 polymorphisms and the risk of gastric cancer A hospital-based case-control study. Gastroenterology 120(5 Suppl 1): A 161

Claudio, P.P.; Radhakrishnan, S.; Zheng, S.; Saunders, M.; Khalili, K.; Giordano, A.; Amini, S.; Sawaya, B.E. 2003: P53 decreases the phosphorylation of polymerase II by cdk9 A novel mechanism for inhibition of HIV-1 gene expression. Journal of Neurovirology 9(Suppl 3): 98-99

Anton, I.; Ortiz Rey, J.A.; San Miguel, P.; Alvarez, C.; De La Fuente, A. 2003: P53 degradation in HPV induced cervical carcinoma occurs before the malignant transformation of dysplastic cells. Modern Pathology 16(1): 180A-181A

Bowen, A.L.; Bosanquet, A.G.; Catovsky, D.; Matutes, E. 1999: P53 deletion and fludarabine-resistance in chronic lymphocytic leukaemia. British Journal of Haematology 105(Suppl 1): 85

Davies, A.; Ottewell, P.D.; Mcnamara, A.V.; Watson, A.J.M.; Jenkins, J.R. 2003: P53 dependent differential expression analysis of etoposide induced stress in the murine small intestine. Gut 52(Suppl 1): A36

Hummer, B.; Li, X.L.; Hassel, B.A. 2001: P53 dependent induction of ISG15 by double-stranded RNA. Journal of Interferon and Cytokine Research 24(Suppl 1): S 116

Joe, J.; Ngai, I.; Goberdhan, A.; Chou, T.C.; Pfister, D.; Shah, J.; Singh, B. 2002: P53 dependent synergism with co-treatment of head and neck squamous cell carcinoma cells with cisplatin and PI3K specific inhibitor. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1138

Soussi, T. 2001: P53 diagnosis in human cancer What utility?. European Journal of Cancer 37(Suppl 6): S139

Lin, K.; Sherrington, P.D.; Stankovic, T.; Dennis, M.; Cawley, J.C.; Pettitt, A.R. 2001: P53 dysfunction as a cause of the drug resistance and short survival of B-CLL patients with non-hypermutated IgVH genes. British Journal of Haematology 113(Suppl 1): 60

Zhao, J.; Mitry, R.R.; Guo, Y.; Lemoine, N.; Habib, N.A. 1999: P53 enhanced the antitumoral efficacy of E1B 55-Kilodalton mutant adenovirus on hepatocellular carcinoma cell line. Gut 44(Suppl 1): A87

Ten Have Opbroek, A.A.W.; Boex, J.J.M. 1999: P53 enhances alveolar epithelial differentiation in the fetal human lung through cell-cycle arrest. FASEB Journal 13(4 Part 1): A354

Liu Dongge; Yang Chongqing; Sun Zhaowu; Man Kaiquan; Zang Xu 2000: P53 expression and histopathology in non-invasive and invasive pituitary adenomas and carcinomas. Chinese Medical Journal (English Edition) 113(4): 366

Elmore, L.W.; Sherman, M.E.; Seidman, J.D.; Kurman, R.J.; Burks, R.T. 2000: P53 expression and mutational status of primary peritoneal micropapillary serous carcinoma with comparison to typical primary peritoneal serous carcinoma. Laboratory Investigation 80(3): 124A

D.J., K.P.; Slooff, M.J.; Peeters, P.M.; Gouw, A.S. 1999: P53 expression in colorectal liver metastases does not influence prognosis after partial liver resection. Hepatology 30(4 Part 2): 280A

Kato, M.; Hirai, H.; Imano, M.; Nishikawa, M.; Nakayama, T.; Izutani, R.; Asano, S.; Kawamura, S.; Kuroda, D.; Nomura, H.; Ohyanagi, H. 1999: P53 expression in gastric cancer cells during chemotherapy induced apoptosis. Journal of Antimicrobial ChemoTherapy 44(Suppl A): 160

Schwerdt, G.; Freudinger, R.; Silbernagl, S.; Gekle, M. 1999: P53 expression in human proximal tubule-derived cells due to exposition to the nephrotoxin ochratoxin A. Physiological Research 48(Suppl 1): S119

Hieken, T.J.; Farolan, M.; D'allessandro, S.; Velasco, J.M. 2000: P53 expression in intraductal breast cancer. Proceedings of the American Association for Cancer Research Annual Meeting 41: 335

Kilicarslan, B.; Karpuzoglu, G. 1999: P53 expression in non small cell lung and small lung carcinomas Relationship with proliferating cell nuclear antigen and cigarette smoking. Virchows Archiv 435(3): 287

Cheah, P.L.; Looi, L.M. 2000: P53 expression in preinvasive cervical squamous intraepithelial neoplasia Has it a story to tell?. Pathology International 50(Suppl): A120

Pavlenko, I.; Matsionis, A. 2003: P53 expression in prostate cancer and its correlation with microvessel density. Virchows Archiv 443(3): 356-357

Tynninen, O.; Paetau, A.; Von Boguslawski, K.; Jaaskelainen, J.; Aronen, H.J.; Paavonen, T. 2000: P53 expression in recurrent gliomas. Pathology International 50(Suppl): A177

Levy, R.; Smith, S.D.; Sadovsky, Y.; Nelson, D.M. 2000: P53 expression in third trimester human trophoblast under normal and hypoxic conditions. Placenta 21(7): A 21

Tynninen, O.; Paetau, A.; Von Boguslawski, K.; Jaaskelainen, J.; Aronen, H.J.; Paavonen, T. 2000: P53 expression in tissue microarray of primary and recurrent gliomas. Brain Pathology 10(4): 575-576

Sauthoff, H.; Heitner, S.; Chen, S.; Pipiya, T.; Rom, W.N.; Hay, J.G. 2002: P53 expression late in the life cycle of a replication-competent adenovirus improves tumor cell killing and deletion of the death protein improves specificity. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1098

Strano, S.; Fontemaggi, G.; Costanzo, A.; Giuliarizzo, M.; Monti, O.; Baccarini, A.; Del Sal, G.; Levrero, M.; Sacchi, A.; Oren, M.; Blandino, G. 2002: P53 family interactions in cancer cells. International Journal of Molecular Medicine 10(Suppl 1): S81

Mack, P.C.; Gandour Edwards, R.; Holland, W.S.; Toscano, S.N.; Deitch, A.D.; Devere White, R.W.; Gumerlock, P.H. 2000: P53 functional status and apoptotic regulation in benign prostatic hyperplasia. Proceedings of the American Association for Cancer Research Annual Meeting 41: 42

Uribarri, A.; Lopez, M.; Aguirregaviria, J.I.; Videgain, J.; Martinez, D.P.ncorbo, M.; Martinez Conde, R.; Aguirre, J.M. 2000: P53 gene alterations in mouthwash and brush cytology in oral leukoplakia. Journal of Oral Pathology and Medicine 29(7): 357

D'erchia, A.M.; Tullo, A.; Pesole, G.; Saccone, C.; Sbisa, E. 2003: P53 gene family Structural, functional and evolutionary features. Current Genomics 4(1): 13-26

Sroller, V.; Madden, C.R.; Halvorson, S.J.; Vilchez, R.A.; Butel, J.S. 2003: P53 gene in simian virus 40-associated non-Hodgkins lymphoma. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1026

Ashavaid, T.F.; Kondkar, A.A.; Bhaduri, A.; Almel, S.; Kapadia, A.; Bharucha, M. 2002: P53 gene mutation analysis in breast cancer using non-isotopic approach and its clinico-pathologic correlation. International Journal of Cancer Suppl (13): 320

Shimokado, K.; Shishida, M.; Hashizume, J.; Onoe, T.; Ishiyama, K.; Urushihara, T.; Kuranishi, F.; Kuroda, Y. 2000: P53 gene mutation and loss of heterozygosity of chromosome 11 in methylcholanthrene-induced mouse sarcomas. Gastroenterology 118(4 Suppl 2 Pt 2): AGA A1411

Yassin, R.R.; Dhillon, S.; Haber, M.; Reynolds, J.C. 2000: P53 gene mutation as a diagnostic approach for esophageal adenocarcinoma. Gastroenterology 118(4 Suppl 2 Pt 1): A39

Elsaleh, H.; Joseph, D.J.; Spry, N.; Iacopetta, B. 1999: P53 gene mutation, microsatellite instability and adjuvant chemotherapy Impact on survival of 494 patients with Dukes C colorectal carcinoma. International Journal of Radiation Oncology Biology Physics 45(3 Suppl): 191

Liu, M.C.; Gelmann, E.P. 2002: P53 gene mutations: case study of a clinical marker for solid tumors. Seminars in Oncology 29(3): 246-257

Benicke, M.; Tannapfel, A.; Busse, C.; Wittekind, C. 2002: P53 gene mutations and INK4a-ARF alterations appear to be two mutually exclusive events in hepatocellular carcinomas. Pathology Research and Practice 198(3): 230

Rys, J.; Schneider Stock, R.; Kruczak, A.; Lackowska, B.; Stelmach, A.; Sokolowski, A.; Markiewicz, D.; Roessner, A.; Niezabitowski, A. 1999: P53 gene mutations and P53 protein overexpression The markers of poor prognosis in breast carcinomas. Virchows Archiv 435(3): 336

Soverini, S.; Terragna, C.; Martinelli, G.; Ottaviani, E.; Amabile, M.; Giannini, B.; Zardini, C.; Buonamici, S.; Zamagni, E.; Cellini, C.; Tosi, P.; Cavo, M.; Tura, S.; Baccarani, M. 2001: P53 gene mutations are a rare event and devoid of prognostic significance in newly diagnosed multiple myeloma patients. Blood 98(11 Part 2): 304b-305b

Jassem, E.; Rosell, R.; Monzo, M.; De Anta, J.M.; Skokowski, J.; Badzio, A.; Roszkiewicz, A.; Jassem, J. 1999: P53 gene mutations are associated with poor prognosis in adenocarcinoma of the lung. European Journal of Cancer 35(Suppl 4): S251

Lambrinakos, A.; Yakubovskaya, M.; Babon, J.J.; Neschastnova, A.A.; Vishnevskaya, Y.V.; D'cuhna, G.; Cotton, R.G.H. 2000: P53 gene mutations in Russian patients with breast cancer detected by chemical cleavage of mismatch. American Journal of Human Genetics 67(4 Suppl 2): 99

Li, L.; Kurooka, M.; Tang, J.; Hongyo, T.; Nakajima, H.; He, H.; Nomura, T. 2001: P53 gene mutations in human esophageal cancer and human esophageal tissues treated with AMN. Mutation Research 483(Suppl 1): S72-S73, 20 October

Hu, Y.C.; Casse, C.; Benoit, N.; Sidransky, D.; Ahrendt, S.A. 2002: P53 gene mutations predict poor survival in stage I non-small cell lung cancer Results of a prospective trial. Proceedings of the American Association for Cancer Research Annual Meeting 43: 832

Gurwitz, D. 1999: P53 gene polymorphism and cancer risk: the debate continues. Clinical Genetics 55(5): 305-306

Temam, S.; Lacau StGuily, J.; Fouret, P. 1999: P53 gene status predicts clinical response of head and neck squamous-cell carcinomas to induction chemotherapy. Virchows Archiv 435(3): 175

Fujiwara, T.; Kataoka, M.; Nakamura, A.; Tanaka, N. 2000: P53 gene therapy for non-small cell lung cancer A preliminary report of phase I trial. Japanese Journal of Pharmacology 82(Suppl 1): 36P

Halachmi, S.; Ahrendt, S.; Chow, J.T.; Halachmi, N.; Yang, S.C.; Wehage, S.; Nativ, O.; Sidransky, D. 2000: P53 genechip assay, computerized mutation analysis and gene sequencing. European Urology 38(4): 508

Wu, X.; Zhao, H.; Amos, C.I.; Shete, S.; Makan, N.; Hong, W.K.; Kadlubar, F.F.; Spitz, M.R. 2001: P53 genotypes, haplotypes and lung cancer susceptibility. International Journal of Molecular Medicine 8(Suppl 1): S71

Dahse, R.; Fiedler, W.; Von Eggeling, F.; Koscielny, S.; Beleites, E.; Ernst, G.; Claussen, U. 1999: P53 genotyping is not an effective concept for molecular testing head and neck cancer. American Journal of Human Genetics 65(4): A123

Parast, M.M.; Abramowsky, C.; Davis, M.; Perez Atayde, A.; Novak, R.; Collins, M.; Husain, A.; Nordberg, M.; Shehata, B.M. 2004: P53 hemizygosity in pleuropulmonary blastoma A study of fifteen cases. Modern Pathology 17(2): 271

Takagi, A.; Kijima, H.; Nagata, J.; Mine, T.; Goto, K.; Ito, M. 2002: P53 hemizygous knockout mice but not APC knockout mice enhance gastric mucosal inflammation induced by H pylori. Gastroenterology 122(4 Suppl 1): A-173

Girio, A.; Chaves, P.; Suspiro, A.; Afonso, A.; Pereira, A.D.; Leitao, C.N.; Almeida, M.O.; Soares, J. 2002: P53 immunoexpression in Barretts adenocarcinoma p53 gene mutation vs binding to mdm2 oncoprotein. Laboratory Investigation 82(1): 127A

Schmitz Draeger, B.J.; Goebell, P.J.; Heydthausen, M.; International Study Initiative, O.B.adder Cancer (Isbc) 1999: P53 immunohistochemistry and prognosis in bladder cancer Updated results of the ISBC combined analysis. European Urology 36(5): 473

Schmitz Draeger, B.J.; Goebell, P.J.; Heydthausen, M. 1999: P53 immunohistochemistry as a prognostic marker in bladder cancer The ISBC combined analysis. Journal of Urology 161(4 Suppl): 153

Pothuri, B.; Ramondetta, L.; Deavers, M.; Barakat, R.; Soslow, R. 2003: P53 immunoreactivity in endometrial cancers developing after radiation treatment for cervical cancer. Modern Pathology 16(1): 206A

Snijders, Peter J.; Breuer, Roderick H.; Sutedja, Tom; Egging, Monique; Meersma, Gert Jan; Van Der Linden, Hans C.; De Vries, Elisabeth G.; Van Der Zee, Ate G.; Postmus, Piet E.; Meijer, Chris J.; Smit, Egbert F. 2000: P53 immunostaining, hTERT and hTR expression in endobronchial premalignant lesions. Proceedings of the American Association for Cancer Research Annual Meeting 41: 536

Alba, M.I.A.; Travolo, A.R.gina F.; Monteiro, E.H.F.; Cury, P.M. 2001: P53 immunostainning is a predictive factor of the presence of metastasis in invasive ductal carcinoma of the breast. Virchows Archiv 439(3): 435

Slaton, J.W.; Benedict, W.F.; Dinney, C.P. 2001: P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology 57(5): 852-859

Vagunda, V.; Smardova, J.; Jandakova, E.; Vagundova, M.; Koukalova, H.; Kovarik, J.; Zaloudik, J. 1999: P53 in breast carcinomas tested by FASAY reveals better correlations with prognostic variables than p53 immunohistochemistry. Breast Cancer Research and Treatment 57(1): 42

Calderon Garciduenas, L.; Rodriguez Alcaraz, A.; Mora Tascareno, A.; Garcia, R.; Osnaya, N.; Villarreal Calderon, A.; Carson, J.; Devlin, R.B.; Van Dyke, T. 2000: P53 in nasal biopsies of children chronically and sequentially exposed to air pollutants. FASEB Journal 14(4): A173

Kurtkaya Yapicier, O.; Scheithauer, B.W.; James, C.D. 2002: P53 in nonneoplastic CNS lesions An immunohistochemical and gene sequencing study. Laboratory Investigation 82(1): 300A

Gansauge, F.; Gansauge, S.; Link, K.H.; Beger, H.G. 1999: P53 in relation to therapeutic outcome of locoregional chemotherapy in pancreatic cancer. Annals of the new York Academy of Sciences 880: 281-287

Lu, X.; Magrane, G.; Gray, J.; Van Dyke, T. 2000: P53 inactivation under natural selection in brain tumor progression without significant chromosomal instability. Proceedings of the American Association for Cancer Research Annual Meeting 41: 717-718

Lin, T.; Reaves, M.; Nicholas, S.; Castro, A.; Green, D. 1999: P53 independent radiation induced apoptosis of small intestinal epithelial cells is independent of Fas, TNF and NO. Gastroenterology 116(4 Part 2): A455

Wall, V.; Lee, S.; Arizti, P.; Borras, A. 1999: P53 induces BRCA1 down regulation through specific promoter control in breast cancer. Journal of the American Geriatrics Society 47(9): S48

Petit, T.; Bearss, D.J.; Subler, M.; Troyer, D.A.; Windle, J.J. 1999: P53 influence in tumor responsivenes to cisplatin and oxaliplatin in a transgenic/knock-out mouse tumor model. Proceedings of the American Association for Cancer Research Annual Meeting 40: 95

Gudkov, A.V.; Komarov, P.G.; Komarova, E.A. 2003: P53 inhibitors and therapeutic use of the same. Official Gazette of the United States Patent and Trademark Office Patents 1272(3)

Levine, A.J.; Finlay, C.A.; Hinds, P.W.; Levine, A.J.; Finlay, C.A.; Hinds, P.W. 2004: P53 is a tumor suppressor gene. Cell 116(2 Suppl): S67

Fortin, A.; Couture, C.; Tetu, B.; Doucet, R.; Raybaud Diogeene, H.; Allard, J.; Murray, D. 2000: P53 is associated with radioresistance in head and neck carcinomas treated by radical radiotherapy. International Journal of Radiation Oncology Biology Physics 48(3 Suppl): 262

Jones, K.H.; Stickrath, C.R.; Cornwell, D.G. 2002: P53 is not required for gamma-tocopheryl quinone to induce apoptosis in cancer cells. FASEB Journal 16(4): A359

Kibbe, M.; Li, J.; Nie, S.; Tzeng, E.; Billiar, T. 1999: P53 is protective against nitric oxide-induced apoptosis in vascular smooth muscle cells. FASEB Journal 13(5 Part 2): A832

Isaacs, J.S.; Saito, S.; Neckers, L.M. 2000: P53 is resistant to leptomycin B- mediated nuclear accumulation and proteasomal degradation in a subset of neuroblastoma cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 41: 622

Yamamoto, M.; Tsukamoto, T.; Sakai, H.; Shirai, N.; Ohgaki, H.; Furihata, C.; Donehower, L.A.; Yoshida, K.; Tatematsu, M. 2000: P53 knockout mice (-/-) are more susceptible than (+/-) or (+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis. Carcinogenesis 21(10): 1891-1897

Murata, T.; Nagasaka, T.; Yoshida, K.; Nakashima, N. 2000: P53 labeling index of biopsy specimens under PTCS is useful in detecting tumor spread of biliary tract carcinomas. Laboratory Investigation 80(3): 188A

Urist, M.; Prives, C. 2002: P53 leans on its siblings. Cancer Cell 1(4): 311-313

Schmidt, U.; Halatsch, M.E.; Ohnuma, T. 1999: P53 mRNA induction after UV irradiation is not modulated by overexpression of deletion-mutant epidermal growth factor receptor in glioblastoma multiforme. Proceedings of the American Association for Cancer Research Annual Meeting 40: 502

Jessen Eller, K.; Steele, M.E.; Begley, G.S.; Reinisch, C.L. 1999: P53 mRNA levels in PCB-exposed Spisula solidissima embryos. FASEB Journal 13(7): A1433

Sheikh, M.S.; Fernandez Salas, E.; Chou, J.; Brooks, K.; Huang, Y.; Fornace, A.J. 2000: P53 mediates apoptosis in a caspase 8-dependent but FADD-independent manner. Proceedings of the American Association for Cancer Research Annual Meeting 41: 555

Siebenhaar, F.; Botchkarev, V.; Sharov, A.; Komarova, E.; Botchkareva, N.; Komarov, P.; Maurer, M.; Gudkov, A.; Gilchrest, B. 2001: P53 mediates apoptotic cell death during hair follicle regression. Journal of Investigative Dermatology 117(2): 428

Pyrzynska, B.; Serrano, V.; Martinez, A.C.; Kaminska, B. 2000: P53 mediates apoptotic cell death triggered by cyclosporin A. Immunology Letters 73(2-3): 228

Shizukuda, Y.kitaka; Matoba, Satoaki; Mian, Omar, Y.; Brenneman, Cynthia, L.; Birdsall, Charles, W.; Sachdev, Vandana; Plehn, Jonathan, F.; Hwang, Paul, M. 2003: P53 mediates doxorubicin-induced cardiac toxicity in mice. Circulation 108(17): IV498

Kelly, K.J.; Plotkin, Z.; Vulgamott, S.L.; Dagher, P.C. 2003: P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: protective role of a p53 inhibitor. Journal of the American Society of Nephrology: Jasn 14(1): 128-138

Lin, X.; Ramamurthi, K.; Mishima, M.; Kondo, A.; Howell, S.B. 2001: P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of tumor cells to the cytotoxic and mutagenic effects of cisplatin. Proceedings of the American Association for Cancer Research Annual Meeting 42: 424

Lin, X.; Ramamurthi, K.; Howell, S.B. 2000: P53 modulates the effects of loss of DNA mismatch repair on the cytotoxicity and mutagenicity of hydrogen peroxide. Proceedings of the American Association for Cancer Research Annual Meeting 41: 263

Donehower, L.A.; Tyner, S.; Venkatachalam, S.; Choi, J.; Dumble, M.; Brayton, C. 2003: P53 mutant mice that display early aging-associated phenotypes. Toxicologic Pathology 31(1): 152-153

Zhang, P.; Wu, J.T. 1999: P53 mutant protein assay Calibrator preparation and procedure development. Clinical Chemistry 45(6 Part 2): A118

Balogh, G.A.; Corte, M.M.; Roncoroni, P.; Nardi, H.; Vincent, E.; Martinez, D.; Cafasso, M.E.; Frizza, A.; Maturi, H.; Ponce, G.; Vincent, E.; Barutta, E.; Lizarraga, P.; Lizarraga, G.; Grimi, C.; Paolillo, E.; Vincent, R.; Quatroquio, R.; 2002: P53 mutant protein in serum could be used as breast cancer marker. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1141

Sun, Y.; Cheung, J.M.; Martel Pelletier, J.; Pelletier, J.P.; Wenger, L.; Altman, R.D.; Howell, D.S.; Cheung, H.S. 1999: P53 mutants up-regulate collagenase-3 expression and they are dominant. Arthritis and Rheumatism 42(9 Suppl): S201

Bazzocchi, G.; Caramelli, E.; Gionchetti, P.; Peruzzo, S.; Rizzello, F.; Di Giacomi, T.; Campieri, M. 1999: P53 mutation analysis in patients with ulcerative colitis in respect to the disease onset. Gastroenterology 116(4 Part 2): A376

Gudlaugsdottir, S.; Hilmarsdottir, H.; Jonasson, J.G.; Thorlacius, S.; Olafsdottir, G.; Tryggvadottir, L.; Ogmundsdottir, H.M.; Eyfjord, J.E. 2001: P53 mutation analysis of breast tumors from a large unselected cohort of BRCA2 mutation carriers and non carriers. American Journal of Human Genetics 69(4 Suppl): 267

De Jong, Koert P.; Gouw, Annette S.H.; Menkema, Lorian; Slooff, Maarten J.H.; Vd Berg, Anke 2000: P53 mutation analysis of resected colorectal liver metastases in relation to immunohistochemistry and prognosis. Hepatology 32(4 Pt 2): 229A

Bradford, C.R.; Zhu, S.; Johnson, G.; Carey, T.E. 2000: P53 mutation and cisplatin sensitivity in laryngeal carcinoma cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 41: 690

Haraoka, S.; Fujiki, T.; Ohshima, K.; Kikuchi, M. 1999: P53 mutation and genetic instability in the early stages of multifocal esophageal squamous cell carcinoma Analysis using micromanipulator-based microdissection and PCR technique. Virchows Archiv 435(3): 293

Liu, Z.H.; Hu, K.B.; Chen, H.P.; Li, L.S. 2000: P53 mutation associated with the renal granuloma formation in patients with Wegener granulomatosis. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 547A

Thompson Hehir, J.; Davies, M.P.A.; Green, J.A.; Halliwell, N.; Joyce, K.A.; Roebuck, M.M.; Salisbury, J.; Sibson, D.R.; Walker, C. 1999: P53 mutation detection by multiplex PCR Detection of novel sequence variation in archival ovarian cancer samples. Proceedings of the American Association for Cancer Research Annual Meeting 40: 206

Smith, G.V.; Ballinger, A.B. 2002: P53 mutation does not influence COX-2 immunoreactivity in gastric adenocarcinoma. Gut 50(Suppl 2): A107-A108

Takada, K.; Kato, J.; Takimoto, R.; Sasaki, K.; Teruui, T.; Niitsu, Y. 2000: P53 mutation is one of mechanisms for escape from type-II TGF-beta receptor-mediated growth inhibitory signal in human gastric cancer cells. Gastroenterology 118(4 Suppl 2 Pt 1): AGA A553

Oglesby, S.D.; Warbrick, E.; Johnston, D.; Dillon, J.; Munro, A.; Hupp, T.; Thompson, A. 2002: P53 mutation rate in esophageal carcinoma is higher than generally accepted. Gastroenterology 122(4 Suppl 1): A-125-A-126

Oglesby, S.D.; Warbrick, E.; Johnston, D.A.; Dillon, J.F.; Munro, A.J.; Hupp, T.R.; Thompson, A.M. 2002: P53 mutation rate in oesophageal carcinoma is higher than generally accepted. British Journal of Cancer 86(Suppl 1): S47

Khan, M.; Marrogi, A.J.; Van Gijssel, H.; Welsh, J.A.; Rahim, H.; Demetrius, A.; Kowdley, K.; Hussain, P.; Okby, N.; Harris, C.C.; Poirier, M. 2001: P53 mutation spectrum in iron overload-associated Hepatocellular Carcinoma. Proceedings of the American Association for Cancer Research Annual Meeting 42: 351

Nelson, H.H.; Wiencke, J.K.; Christiani, D.C.; Mark, E.J.; Wain, J.C.; Kelsey, K.T. 1999: P53 mutation spectrum in non-small cell lung cancer Results from a prospective study. American Journal of Human Genetics 65(4): A312

Bauer, J.A.; Oliver, C.; O'connell, K.; Wang, S.; Carey, T.E.; Bradford, C.R. 2003: P53 mutation status and induction of apoptosis using a novel Bcl-xL inhibitor in head and neck squamous cell carcinoma cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 44: 332-333

Schroeder, J.C.; Conway, K.; Taylor, J.A. 2001: P53 mutation, exposure, and genetic susceptibility in a case-control study of bladder cancer. American Journal of Epidemiology 153(11 Suppl): S122

Illei, P.B.; Zhao, Z.; Huang, H.Y.; Ladanyi, M. 2003: P53 mutation, p16/CDKN2A deletion, and EWS-FL11 fusion type in Ewing sarcoma An analysis of 60 cases. Modern Pathology 16(1): 14A

Khan, M.A.; Hussain, P.; Marrogi, A.J.; Hofseth, L.; Okby, N.; Ishak, K.G.; Harris, C.C. 2000: P53 mutational spectrum in hepatocellular carcinoma associated with hemochromatosis, an iron-overload disease. Proceedings of the American Association for Cancer Research Annual Meeting 41: 234

Drenning, S.D.; Yip, L.; Marcovitch, A.; Sidransky, D.; Gooding, W.; Grandis, J.R.bin 2001: P53 mutational status contributes to Bcl-2 and Bax protein expression levels in squamous cell carcinoma of the head and neck. Proceedings of the American Association for Cancer Research Annual Meeting 42: 225

Amikam, D.; Davidson, S.; Leshanski, L.; Ben Arush, M.W.; Postovsky, S.; Peretz, T.; Salmon, A.; Abeliovich, D.; Sagi, M. 2003: P53 mutations A novel germline aberration and a rare transversion in a supratentorial primitive neuroectodermal tumor Clinical implications. International Journal of Molecular Medicine 12(Suppl 1): S8

Reddy, A.; Crook, T.; Weller, I.; Crawford, D.H. 2000: P53 mutations An early event in AIDS-associated non Hodgkins lymphomas ?. British Journal of Cancer 83(Suppl 1): 15

Peters, G.J.; Backus, H.H.J.; Wouters, D.; Ferreira, C.G.; Poupon, M.F.; Pinedo, H.M. 2001: P53 mutations affect drug sensitivity by altering thymidylate synthase levels rather than apoptotic pathways. International Journal of Molecular Medicine 8(Suppl 1): S80

Mares, J.; Babjuk, M.; Trkova, M.; Duskova, J.; Soukup, V.; Goetz, P.; Sedlacek, Z. 2002: P53 mutations and PAX5 and SHB genes expression in superficial bladder cancer. European Journal of Human Genetics 10(Suppl 1): 89

Bonner, M.R.; Freudenheim, J.L.; Ambrosone, C.B.; Graham, S.; Vena, J.E.; Moysich, K.B.; Krishnan, S.; Shields, P.G. 2001: P53 mutations and breast cancer established risk factors. American Journal of Epidemiology 153(11 Suppl): S109

Popp, W.; Vahrenholz, C.; Plogmann, H.; Norpoth, K. 1999: P53 mutations and codon 213 polymorphism in lung cancers of former uranium miners. Proceedings of the American Association for Cancer Research Annual Meeting 40: 244

Kim, S.S.; Bhang, C.S.; Lee, H.S.; Chae, H.S.; Chung, I.S.; Park, D.H. 2001: P53 mutations and microsatellite instabilities in the subtype of intestinal metaplasia of the stomach and its role as a precancerous lesion. Gastroenterology 120(5 Suppl 1): A299-A300

Gottschlich, S.; Maass, J.D.; Werner, J.A.; Rudert, H. 2000: P53 mutations and over-expression in head and neck cancer. European Archives of Oto-Rhino-Laryngology 257(2): 111

Welsh, J.A.; Khan, M.A.; Marrogi, A.J.; Shields, P.G.; Harris, C.C. 2000: P53 mutations are early events in the tobacco-associated human lung carcinogenesis. Proceedings of the American Association for Cancer Research Annual Meeting 41: 873

Kannio, A.; Benhamou, S.; Nyberg, F.; Anttila, S.; Mukeria, A.; Fortes, C.; Boffetta, P.; Husgafvel Pursiainen, K. 2002: P53 mutations as a biomarker in female lung cancer. Proceedings of the American Association for Cancer Research Annual Meeting 43: 403

Ren, Z.P.; Mcniff, J.; Gasparro, F.P. 1999: P53 mutations at psoralen photochemical hot spots - Rare but significant events in PUVA induced skin cancers. Journal of Investigative Dermatology 112(4): 657

Mangray, S.; King, T.C.; Walsh, K.; Akerley, W.; Fan, A.; Safran, H. 2000: P53 mutations do not predict response to paclitaxel in non-small cell lung cancer. Laboratory Investigation 80(3): 213A

Krishnadath, K.K.; Wang, K.K.; Taniguchi, K.; Sebo, T.J.; Buttar, N.S.; Anderson, M.A.; Lutzke, L.S.; Wongkeesong, L.M.; Liu, W. 2001: P53 mutations in Barretts esophagus predict poor response to photodynamic therapy. Gastroenterology 120(5 Suppl 1): A 413

Done, S.J.; Eskandarian, S.; Redston, M.; Andrulis, I.L. 2001: P53 mutations in DCIS not associated with invasive breast cancer. Laboratory Investigation 81(1): 25A

Ananthaswamy, H.N.; Conti, C.; Ouhtit, A.; Gorny, A.; Khaskina, P. 1999: P53 mutations in UV-induced skin tumors from XPC-deficient mice. Photochemistry and Photobiology 69(SPEC ISSUE ): 3S

Rosenstein, B.; Phelps, R.; Weinstock, M.; Bernstein, J.; Gordon, M.; Rudikoff, D.; Kantor, I.; Shelton, R.; Lebwohl, M. 1999: P53 mutations in basal cell carcinomas arising in routine sunscreen users. Photochemistry and Photobiology 69(SPEC ISSUE ): 33S

Rosenstein, B.S.; Phelps, R.G.; Weinstock, M.A.; Bernstein, J.L.; Gordon, M.L.; Rudikoff, D.; Kantor, I.; Shelton, R.; Lebwohl, M.G. 1999: P53 mutations in basal cell carcinomas arising in routine users of sunscreens. Photochemistry and Photobiology 70(5): 798-806

Li, S.Q.; Bhardwaj, T.; Rohan, T.E.; Kandel, R. 2003: P53 mutations in benign breast tissue. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1131

Narendran, A.; Ganjavi, H.; Connor, A.; Keystone, E.; Freedman, M.H.; Malkin, D. 2002: P53 mutations in bone marrow stromal cells may play a critical role in leukemia through the induction of angiogenic and lymphangiogenic factors. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1053

Wang, J.; Shepherd, T.; Tolbert, D.; Noffsinger, A.; Stemmermann, G.; Fenoglio Preiser, C.M. 2001: P53 mutations in gastric cancer in a population of the United States. Proceedings of the American Association for Cancer Research Annual Meeting 42: 224

Tsuchida, N.; Kannan, K.; Munirajan, A.K.; Jin, F.; Gao, C.F.; Nakajima, T.; Shanmugam, G. 2000: P53 mutations in head and neck cancer of India, and cell growth control in a novel p53 mutant. International Journal of Molecular Medicine 6(Suppl 1): S43

Berggren, P.; Steineck, G.; Adolfsson, J.; Borgstrom, E.; Hansson, J.; Norming, U.; Sandstedt, B.; Wijkstrom, H.; Hemminki, K. 1999: P53 mutations in human urinary bladder cancer. British Journal of Cancer 80(Suppl 2): 71

Jiffar, T.; Badgwell, D.; Pelley, R.P.; Strickland, F.M. 2001: P53 mutations in murine skin tumors induced by combined ethanol, aloe emodin and UV radiation resemble mutations in human skin cancer. Proceedings of the American Association for Cancer Research Annual Meeting 42: 807

Oglesby, S.D.; Warbrick, E.; Johnston, D.A.; Dillon, J.F.; Munro, A.J.; Hupp, T.R.; Thompson, A.M. 2002: P53 mutations in oesopahgeal adenocarcinoma are common and are associated with disease response. Gut 50(Suppl 2): A92

Friedrich, R.E.; Giese, M.; Riethdorf, S.; Riethdorf, R.; Loening, T. 1999: P53 mutations in oral smears of patients with squamous cell carcinoma of the oral cavity. Anticancer Research 19(6D): 5676

Toncheva, D.; Atanassova, S.; Savov, A.; Videnov, R.; Kovacheva, A.; Zaharieva, B.; Tzenova, V.; Kremensky, I. 1999: P53 mutations in spontaneous abortions. European Journal of Human Genetics 7(Suppl 1): 127

Tessitore, A.; Ricevuto, E.; Di Rocco, C.Z.; Cannita, K.; Sinopoli, N.T.; Guilino, A.; Marcheitt, P.; Ficorella, C.; Martinotti, S. 1999: P53 mutations in sporadic breast cancer Comparative analysis by FAMA and SSCP. Proceedings of the American Association for Cancer Research Annual Meeting 40: 690

Conway, K.; Edmiston, S.N.; Cui, L.; He, M.; Pang, J.; Mistry, K.; Drouin, S.; Li, Y.; Liu, E.; Geradts, J.; Millikan, R.; Newman, B. 1999: P53 mutations in the Carolina Breast Cancer Study Spectrum and clinical associations. Proceedings of the American Association for Cancer Research Annual Meeting 40: 194

Rocha, G.A.; Magalhaes, P.P.; Queiroz, D.M.M.; Nogueira, A.M.F.; Camargo, A.A.; Teixeira, L.M.; Simpson, A.J.G. 2001: P53 mutations in the gastric mucosa of Helicobacter pylori-positive patients with gastric carcinoma. Gut 49(Suppl 11): A58

Greiner, T.C.; Farrell, B.T.; Weisenburger, D.D.; Hoeck, L.; Armitage, J.O.; Staudt, L.; Chan, W.C. 2002: P53 mutations may explain the decreased survival in the activated B-like subgroup of diffuse large B-cell lymphomas. Laboratory Investigation 82(1): 242A

Stern, M.C.; Schroeder, J.C.; Dorsey, K.C.; Taylor, J.A. 2002: P53 mutations, DNA repair gene polymorphisms, and bladder cancer risk. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1020

Shin, D.Y.; Yun, J. 1999: P53 negatively regulates the human cdk1 expression via NF-Y transcription factor. FASEB Journal 13(7): A1461

Xu, H.; El Gewely, M.R. 2000: P53 network Its downstream regulated genes. Biochemical Society Transactions 28(5): A227

Fleshner, N.E.; Kapusta, L.; Ezer, D.; Klotz, L.; Herschorn, S. 2000: P53 nuclear accumulation is not associated with prolonged disease free survival among patients with node positive transitional cell carcinoma of the bladder. Journal of Urology 163(4 Suppl): 234-235

Shupe, T.D.; Rosano, T.; Yin, L.; Sell, S. 2001: P53 null mice maintain high levels of AFB1 activating P450s but fail to develop appropriate levels of AFB1 detoxifying GSTs during the first four months of age. Proceedings of the American Association for Cancer Research Annual Meeting 42: 162

Shupe, T.D.; Rosano, T.; Sell, S. 2000: P53 null mice show impaired GST mediated hepatic detoxification of aflatoxin B1. Proceedings of the American Association for Cancer Research Annual Meeting 41: 839

Buller, R.E.; Sood, A.K.; Shahin, M.S.; Anderson, B.; Sorosky, J.I. 2000: P53 null mutations Further explorations. Proceedings of the American Association for Cancer Research Annual Meeting 41: 276

Tae, K.; El Naggar, A.K.; Zhang, P.; Feng, L.; Lee, J.J.; Hong, W.K.; Hittelman, W.N.; Shin, D.M. 2000: P53 overexpression and angiogenesis in head and neck squamous cell carcinoma. Proceedings of the American Association for Cancer Research Annual Meeting 41: 687

Shibata, A.; Garcia, M.I.; Longacre, T.A.; Puligandla, B.; Parsonnet, J.; Vogelman, J.; Orentreich, N.; Habel, L.A. 2000: P53 overexpression and cell proliferation index in gastric cancer by anatomic subsite. American Journal of Epidemiology 151(11 Suppl): S77

Boardman, L.; Rand, A.; Batts, K.P.; Mcdonnell, S.K.; Petersen, B.J.; Zaheer, S.; Pemberton, J.H.; Karnes, W.E.Jr 1999: P53 overexpression and k-ras mutation in early stage rectal cancer do not correlate with recurrence. Gastroenterology 116(4 Part 2): A379

Zigeuner, R.; Ratschek, M.; Schips, L.; Tsybrovskyy, O.; Langner, C. 2004: P53 overexpression in metastases of renal cell carcinomas is related to metastatic sites. Journal of Urology 171(4 Suppl): 204

Magalhães, S.M.; Ponte, L.P.; Valdeci A Ferreira, F.; Rocha Filho, F.D. 1999: P53 overexpression in refractory anemia. An immunohistochemical analysis of bone marrow biopsies. Haematologica 84(4): 377-378

Vijayvargiya, A.; Laver, N.; Perepletchikov, A.; Pang, X.; Mithoefer, A.; Freeman, R. 2003: P53 overexpression in transplant patients with skin squamous cell carcinoma. Modern Pathology 16(1): 300A

Liegl, B.; Beham Schmid, C.; Regauer, S. 2003: P53 overexpression in vulvar lichen sclerosus does not identify patients at risk for developing a SCC. Modern Pathology 16(1): 94A

Ribeiro Junior, U.; Safatle Ribeiro, A.V.; Sakai, P.; Gama Rodrigues, J.J.; Okumura, M.; Ishioka, S.; Finkelstein, S.D.; Reynolds, J.C.; Habr Gama, A.; Corbett, C.E. 2000: P53 overexpression is associated with increased risk of malignancy in the megaesophagus but it is not present in megacolon due to Chagas disease. Gastroenterology 118(4 Suppl 2 Pt 2): SSAT A1529

Gregorc, V.; Ludovini, V.; Pistola, L.; Darwish, S.; De Angelis, V.; Minotti, V.; Bellezza, G.; Sidoni, A.; Bucciarelli, E.; Tonato, M. 2001: P53 overexpression predicts the resistance to chemotherapy in advanced non small cell lung cancer. European Journal of Cancer 37(Suppl 6): S118

Terry, M.B.; Hibshoosh, H.; Mansukhani, M.; Pringle, M.Y.; Harpaz, N.; Waye, J.D.; Neugut, A. 2001: P53 overexpression, epidemiologic risk factors, and early colorectal neoplasia. Proceedings of the American Association for Cancer Research Annual Meeting 42: 35

Cummings, M.; Higginbottom, K.; Newland, A.C.; Allen, P.D. 2001: P53 overrides the etoposide-induced G2/M block in K562 cells, leading to enhanced apoptosis. British Journal of Haematology 113(Suppl 1): 25

Le Pelletier, F.; Soufir, N.; de La Salmoniere, P.; Janin, A.; Basset-Seguin, N. 2001: P53 Patches are not increased in patients with multiple nonmelanoma skin cancers. Journal of Investigative Dermatology 117(5): 1324-1325

Bates, A.; Reddy, G.; Gupta, R.; Radding, C.; Zarling, D. 2000: P53 peptide and small molecule drug regulators of human Rad51. Cancer Gene Therapy 7(12): S7

Bischoff, F.Z.; Dang, D.; Poindexter, A.; Mitchell Leef, D.; Buster, J.E.; Simpson, J.L.igh 2003: P53 perturbations in endometriosis detected by quantitative real-time PCR Further evidence of late somatic DNA alterations. Fertility and Sterility 80(Suppl 3): S35

Nieminen, A.; Schneider, E.; Agani, F. 2003: P53 phosphorylation regulates hypoxia-mediated apoptotic death in tumor cells. Toxicological Sciences 72(S-1): 356

Thanikachalam, M.; Li, S.; Simmonds, A.; Cheung, M.; Vazquez Padron, R.; Liotta, C.A.; Gambotto, A.; Aitouche, A.; Pham, S.M. 2004: P53 plays a significant role in the pathogenesis of Allograft Vasculopathy. Journal of Heart and Lung Transplantation 23(2S): S125

Ahomadegbe, J.C.; Fogel, S.; Janot, F.; Benard, J.; Riou, G. 1999: P53 polymorphism at codon 72 No evidence for a role in head and neck carcinogenesis. Proceedings of the American Association for Cancer Research Annual Meeting 40: 693

Gasco, M.; Sullivan, A.; Bergamaschi, D.; Hiller, L.; Trigiante, G.; Smith, P.; Farrell, P.; Elgueta, C.; Merlano, M.; Numico, G.; Lu, X.; Kaelin, W.G.; Crook, T. 2003: P53 polymorphism is a major determinant of treatment outcome in head and neck cancer via its opposing effects on the properties of wild-type and mutant proteins. Proceedings of the American Association for Cancer Research Annual Meeting 44: 382

Kojima, S.; Goto, Y.; Iwai, N.; Takagi, S.; Yasuno, S.; Yamauchi, R.; Miyazaki, S.; Nonogi, H. 2001: P53 polymorphism of tumor suppressor protein is associated with luminal narrowing after coronary stent placement. Circulation 104(17): 2; 545

Mahasneh, A.; Abdel Hafiz, S. 2003: P53 polymorphisms and haplotypes in Jordanian ethnic groups, breast cancer and lung adenocarcinoma patients. Molecular and Cellular Proteomics 2(9): 989

Huang, S.; Liu, L.; Hosoi, H.; Dilling, M.B.; Shikata, T.; Germain, G.S.; Houghton, P.J. 2000: P53 prevents rapamycin-induced apoptosis in human tumor cells and murine embryo fibroblasts deficient in p53 function. Proceedings of the American Association for Cancer Research Annual Meeting 41: 754

Thor, A.; Edgerton, S.; Fritz, B.; Lynch, K.; Klein, K. 2002: P53 profiling of human breast cancer Interactions with smoking. Laboratory Investigation 82(1): 53A

Kibbe, M.; Li, J.; Nie, S.; Billiar, T.; Tzeng, E. 1999: P53 protects against nitric oxide mediated apoptosis in vascular smooth muscle cells. Acta Physiologica Scandinavica 167(Suppl 645): 10

Younes, M.; Ertan, A.; Lechago, J. 2003: P53 protein and malignant progression in Barretts metaplasia. American Journal of Gastroenterology 98(5): 1200-1201

Gervaz, P.A.; Bouzourene, H.; Cerottini, J.P.; Benhattar, J.; Chaubert, P.; Saraga, E.; Bosman, F.; Givel, J.C. 1999: P53 protein and prognosis in Dukes B colorectal cancer. Gastroenterology 116(4 Part 2): A410

Miner, Z.; Kulesz Martin, M. 1999: P53 protein associated with the splicing factor, hnRNP A2, found in mammary cell lysates. Proceedings of the American Association for Cancer Research Annual Meeting 40: 703

Goto, S.; Gordon, A.; Morimoto, S.; Izumi, M.; Honma, M.; Watanabe, M.; Yatagai, F. 2000: P53 protein contributed to repair of double strand break. Journal of Radiation Research 41(4): 399

Adams, R.G.ovanni Hakeem; Bigler, L.B.; Streckfus, C.F. 2001: P53 protein detection as a diagnostic tool for cancer. FASEB Journal 15(4): A559

Ioakim Liossi, A.; Pantazopoulos, D.; Karakitsos, P.; Athanassiadou, P.; Stergiou, E.; Karkabassi, A.; Athanassiades, P.; Davaris, P. 1999: P53 protein expression and proliferative activity in renal cell carcinomas. European Journal of Cancer 35(Suppl 4): S109

Soleiman, M. 2001: P53 protein expression and steroid receptors status in primary breast cancer. Clinical Chemistry and Laboratory Medicine 39(Special Suppl): S400

Navarro, M.N.; Gimenez, A.; Sola, J.; Bermejo, J. 1999: P53 protein expression in Barretts esophagus. Virchows Archiv 435(3): 247

Kim, H.R.; Park, M.I.; Jung, H.Y.; Yang, S.G.; Hong, W.S.; Min, Y.I.; Yu, E.S. 1999: P53 protein expression in gastric dysplasia and carcinoma. Gastroenterology 116(4 Part 2): A439

Panjehpour, Masoud; Coppolla, Domenico; Overholt, Bergein F.; Vo Dinh, Tuan; Overholt, Suzanne 2002: P53 protein expression in neosquamous mucosa after photodynamic therapy of high grade dysplasia in Barretts esophagus. Gastroenterology 122(4 Suppl 1): A-350

Fagundes, R.B.; Barros, S.G.; Melo, C.R.; Wagner, M.B.; Tollens, P.; Moreira, L.F.; Putten, A.C. 2000: P53 protein in esophageal mucosa of individuals at high-risk for squamous cell carcinoma of the esophagus. Gastroenterology 118(4 Suppl 2 Pt 1): A36

Fanzo, J.C.; Reaves, S.K.; Cui, L.B.; Zhu, L.; Wu, J.Y.J.; Wang, Y.R.; Lei, K.Y. 2001: P53 protein levels, cyclin-dependent kinase inhibitor p21, bcl-2 family genes, and caspase-3 activity are altered by cellular zinc status in human aortic endothelial cells. FASEB Journal 15(4): A257

Sun, W.; Zhang, P.L.; Herrera, G.A. 2002: P53 protein overexpression correlates with increased Ki-67 proliferative activity in urothelial dysplasia of bladder. Laboratory Investigation 82(1): 183A

Dror, Y. 2002: P53 protein overexpression in Shwachman-Diamond syndrome. Archives of Pathology and Laboratory Medicine 126(10): 1157-8; author reply 1158

Xie, H.; Kleiner, D.; Chow, W.H.; Risch, H.A.; Gammon, M.D.; Vaughan, T.L.; Mayne, S.T.; Rotterdam, H.; Farrow, D.C.; Fraumeni, J.F. 2000: P53 protein overexpression in esophageal and gastric carcinomas. Proceedings of the American Association for Cancer Research Annual Meeting 41: 599

Momand, J.; Wu, H.H.; Thomas, J.A.; Makmura, L.; Areopagita, A.; Furuta, S.; Munoz, A. 2000: P53 protein oxidation in cultured cells in response to PDTC A novel method for relating the amount of p53 oxidation in vivo to the regulation of p53-responsive genes. Free Radical Biology and Medicine 29(Suppl 1): S59

Galmarini, C.M.; Kamath, K.; Vanier, A.; Falette, N.; Puisieux, A.; Jordan, M.A.; Dumontet, C.M. 2002: P53 protein regulates the composition and dynamics of microtubules. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1139

Rose, S.L.; Robertson, A.D.; Goodheart, M.J.; Buller, R.E. 2003: P53 protein structural alteration alone does not modify ovarian cancer survival. Proceedings of the American Association for Cancer Research Annual Meeting 44: 700-701

Conseiller, E.; Bracco, L. 2001: P53 protein variants and therapeutic uses thereof. Official Gazette of the United States Patent and Trademark Office Patents 1253(1)

Kulesz Martin, M.; Liu, Y.; Kisiel, N.; Lee, L. 1999: P53 proteins in response to DNA damage. Proceedings of the American Association for Cancer Research Annual Meeting 40: 700

Machtens, S.; Kuczyk, M.; Serth, J.; Bathke, W.; Minssen, A.; Jonas, U. 2000: P53 regulated maspin protein expression determines recurrence-free survival of patients with localized prostate cancer. European Urology 38(4): 491

Nelson, A.C.; Geske, F.J.; Lieberman, R.C.; Gerschenson, L.E. 2001: P53 regulates DNA repair after UV radiation. FASEB Journal 15(5): A941

Laws, A.M.; Osborne, B.A. 2002: P53 regulates T cell development through Notch1. FASEB Journal 16(4): A343

Goltsov, A.A.; Ren, C.; Wang, J.; Yang, G.; Tahir, S.; Li, L.; Timme, T.; Thompson, T.C. 2001: P53 regulates the expression of a novel four transmembrane protein PERP/PIGPC1 in mouse and human prostate cancer. Proceedings of the American Association for Cancer Research Annual Meeting 42: 218

Zhang, Y.; Wang, T.Y.; Cheng, X.K.; Wu, N.H.; Shen, Y.F. 2000: P53 regulates the expression of human hsp90b gene. Biochemical Society Transactions 28(5): A243

Navone, N.M.; Yang, J.; Fizazi, K.; Sikes, C.; Vazquez, E.; Martinez, L.A. 2001: P53 regulates the response to growth factor deprivation and androgen withdrawal in prostate cancer cells in vitro and in vivo. Proceedings of the American Association for Cancer Research Annual Meeting 42: 229

Fang, L.; Huang, H.; Rose, J.L.; Hoyt, D.G. 2004: P53 regulates the sensitivity of mouse lung endothelial cells to the DNA-damaging agent, cisplatin. FASEB Journal 18(4-5): Abstract 221

Perry, M.E. 2003: P53 regulation by Mdm2. Tumor Biology 24(Suppl 1): 2

Itoh, T.; Linn, S. 2003: P53 regulation is abnormal in xeroderma pigmentosum group E diploid human fibroblasts. Journal of Investigative Dermatology 121(1): 0134

Nelson, B.; Elliott, M.; Mcdowell, H.P.; White, M.R. 2001: P53 response and function in neuroblastoma cell lines. Biochemical Society Transactions 29(5): A115

Hoh, J.; Dewan, A.; Jin, S.; Edington, J.; Parrado, T.; Ott, J.; Levine, A.J. 2003: P53 responsive DNA elements in the human genome. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1387

Cesare, A.J.; Subrmanian, D.; Stansel, R.M.; Degtyareva, N.; Lee, S.; Griffith, J.D. 2003: P53 role in direct surveillance of genome integrity. Toxicologic Pathology 31(1): 159-160

Mulhall, J.P.; Barnas, J. 2004: P53 sequencing in Peyronies disease plaque-derived fibroblasts. Journal of Urology 171(4 Suppl): 381

Gottschlich, S.; Hoffmann, M.; Goeroegh, T.; Maass, J.D.; Rudert, H.; Maune, S. 2002: P53 serum antibodies as tumor marker in head and neck cancer. Anticancer Research 22(1B): 534

Zhang, Z.W.; Patchett, S.E.; Farthing, M. 1999: P53 signal transduction pathway is not essential for H pylori associated apoptosis and cell growth inhibition in gastric cells. Gastroenterology 116(4 Part 2): A159

Stewart, Z.A.; Pietenpol, J.A. 2001: P53 Signaling and cell cycle checkpoints. Chemical Research in Toxicology 14(3): 243-263

Bodis, S.; Pruschy, M. 2003: P53 signaling and novel mechanisms for targeted radiosensitizers. EJC Suppls 1(5): S27

Kuroda, J.; Kimura, S.; Segawa, H.; Kobayashi, Y.; Yoshikawa, T.; Ottmann, O.; Maekawa, T. 2003: P53 signaling cascade independent apoptotic induction by zoledronate in BV173, leukemic cell line. Experimental Hematology (New York) 31(7 Suppl 1): 95-96

Wu, J.; Eckard, J.; Rossman, T.G.; Yang, C.; Frenkel, K. 2003: P53 signaling pathway involved in arsenite-induced HOS cell transformation and its prevention by caffeic acid phenethyl ester. Toxicological Sciences 72(S-1): 269

Zilfou, J.T.; Hoffman, W.H.; Murphy, M.E. 2000: P53 stability is regulated by the co-repressor protein mSin3a. Proceedings of the American Association for Cancer Research Annual Meeting 41: 716-717

Trovato, R.; Kislyakova, T.; Cereseto, A.; Takemoto, S.; Casareto, L.; Gessain, A.; Watanabe, T.; Waldmann, T.; Franchini, G. 1999: P53 stabilization and functional impairment and frequent deletion of p16INK in uncultured ATLL cells. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 20(4): A15

Athar, M.; Tang, X.; Kopelovich, L.; Bickers, D.R. 2003: P53 stabilization by CP-31398 restores wild type p53-dependent function in ultraviolet B -irradiated murine skin and in A431 cells. Journal of Investigative Dermatology 121(1): 0208

Li, G.; Luu, Y.; Cheung, K.; Bush, J. 2001: P53 stabilizing compound, CP31398, induces apoptosis by activating caspases. Journal of Investigative Dermatology 117(2): 480

Hauser, U.; Scheckenbach, K.; Balz, V.; Grenman, R.; Erjala, K.; Hoffmann, T.K.; Bier, H. 2002: P53 status and sensitivity to radio- and chemotherapy in 30 cell lines of squamous cell carcinomas of the head and neck. Proceedings of the American Association for Cancer Research Annual Meeting 43: 129

Catalano, E.; Calafati, S. 2001: P53 status and the expression of cyclin-dependent kinase inhibitors p21waf-1, p16ink4 and p27kip1 in non-Hodgkins lymphomas. Laboratory Investigation 81(1): 158a, Uary

Wheeler, J.M.D.; Warren, B.F.; Mortensen, N.J.M.c; Biddolph, S.C.; Elia, G.; Bodmer, W.F. 2000: P53 status and the regression of rectal cancer following preoperative chemoradiotherapy. Gut 46(11): A85

Ma, Y.; Yuan, R.; Meng, Q.; Chen, D.; Goldberg, I.; Rosen, E.M.; Fan, S. 2000: P53 status as a determinant of response to arsenic trioxide in human Burkitts lymphoma, prostate and breast cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting 41: 753

Jiang, X.H.; Lam, S.K.; Lin, M.C.M.; Cho, C.H.; Lai, K.C.; Kung, H.F.; Yang, D.; Wong, B.C.Y. 2001: P53 status determines nuclear factor-kappaB response in triptolide-induced apoptosis in gastric cancer. Proceedings of the American Association for Cancer Research Annual Meeting 42: 659

Wang, Y.; Liau, L.M.; Cloughesy, T.F.; Mischel, P.S. 2003: P53 status determines the cell fate of glioblastoma cells in response to SN-38. Proceedings of the American Association for Cancer Research Annual Meeting 44: 526

Leibovich, B.C.; Cheng, L.; Mahoney, D.W.; Plevak, M.F.; Bostwick, D.G. 1999: P53 status predicts recurrence and progression of low stage urothelial carcinoma of the bladder. Journal of Urology 161(4 Suppl): 150

Gibbs, N.K.; Traynor, N.J. 2001: P53 transactivation photosensitised by the skin phototumorigen lomefloxacin, is not mediated by DNA strand breakage or H2O2. British Journal of Dermatology 144(3): 675

Regula, K.; Kirshenbaum, L.A. 2000: P53 triggers mitochondrial cytochrome C release, caspase activation, and apoptosis of ventricular myocytes independent of DNA binding and gene transcription. Canadian Journal of Cardiology 16(Suppl F): 116F

Krause, K.; Wiedmann, M.; Haugwitz, U.; Mossner, J.; Engeland, K. 2000: P53 tumor suppressor family members can repress transcription of the cdc25C cell cycle phosphatase. Gastroenterology 118(4 Suppl 2 Pt 1): A48

Ozturk, M.; Unsal, K. 1999: P53 tumor suppressor gene Its role in DNA damage response and cancer. Dizdaroglu, M , Karakaya, A E NATO ASI Series Series A Life Sciences; Advances in DNA damage and repair: Oxygen radical effects, cellular protection, and biological consequences 371-376

Katiyar, S.; Hedau, S.; Gopalkrishna, V.; Das, B.C. 1999: P53 tumor suppressor gene mutations in a spectrum of human cancers in India. Proceedings of the American Association for Cancer Research Annual Meeting 40: 272-273

Shibata, A. 2002: P53 tumor suppressor gene mutations in cancer associated with bacterial and parasitic infections. American Journal of Epidemiology 155(11 Suppl): S27

Ashcroft, M.; Vousden, K.H. 2001: P53 tumor suppressor protein. Fisher, David E Author Cancer Drug Discovery and Development Tumor suppressor genes in human cancer 159-181

Dmitrieva, N.; Michea, L.; Burg, M. 2001: P53 tumor suppressor protein protects renal inner medullary cells from hypertonic stress by restricting DNA replication. FASEB Journal 15(5): A850

Ryan, D.; Butcher, D.; Burke, L.; Gall, A.; Galateau Salle, F.; Nicholson, A.G.; Sheppard, M.N. 2001: P53, Bcl2, BAX and retinoblastoma gene expression in tumourlets and typical carcinoid tumours of lung. Laboratory Investigation 81(1): 226A

Kharatishvily, T.K.; Stepanova, E.; Mousaev, E.R.; Aliev, M.D. 2002: P53, HER-2/neu and VEGF determined immunohistochemically in chondrosarcoma. International Journal of Cancer Suppl (13): 274

Shukla, D.; Nordberg, M.L.; Abreo, F.; Shi, R. 2004: P53, Ki-67, HER-2/neu, estrogen receptor, and progesterone expression do not predict lymph node metastasis in African American breast cancer patients. Archives of Pathology and Laboratory Medicine 128(2): 149

Morgan, M.B.; Cowper, S. 1999: P53, MDM2, and p27 in porokeratosis A unifying pathogenesis?. Modern Pathology 12(1): 61A

Ormsby, A.H.; Petras, R.E.; Gramlich, T.L.; Fazio, V.W.; Remzi, F.H.; O'riordain, M.G.; Goldblum, J.R. 2001: P53, MIB-1, BAX and BCL-2 expression in anal transitional zone dysplasia following ileo-pouch anal anastomosis for inflammatory bowel disease. Gastroenterology 120(5 Suppl 1): A 268

Petroni, G.; Krupski, T.; Frierson, H.F.Jr.; Theodorescu, D. 1999: P53, RB proteins and microvessel density are long term survival markers in localized carcinoma of the prostate. Journal of Urology 161(4 Suppl): 241

Lowe, S.W. 1999: P53, apoptosis, and chemosensitivity. Hickman, J A, Dive, C Cancer Drug Discovery and Development; Apoptosis and cancer chemotherapy 21-36

Ibrahim, M.M.; El Mesidi, S.M.; Gaber, M.H.; Nasr, S.M. 2002: P53, apoptotic index and P-glycoprotein as predictive of treatment outcome in Egyptian patients with head and neck squamous cell carcinoma. International Journal of Cancer Suppl (13): 95-96

Baltaci, S.; Yesilli, C.; Turkolmez, K.; Beduk, Y.; Gogus, O. 2000: P53, bcl-2 and BAX immunoreactivity as predictors of response and outcome following chemotherapy for metastatic germ cell testicular tumors. European Urology 38(4): 527

Batistatou, A.; Zolota, V.; Tiniakos, D.G.; Scopa, C.D. 1999: P53, bcl-2 and Bax expression in thyroid carcinomas. Virchows Archiv 435(3): 221

Balzi, M.; Faraoni, P.; Nostro, M.C.; Ferullo, S.; Wilson, J.W.; Cianchi, F.; Potten, C.S.; Becciolini, A. 2000: P53, bcl-2 and bcl-w expression in colorectal adenocarcinoma. International Journal of Biological Markers 15(3): 258

Darvishian, F.; Bhargava, R.; Marshall, D.S.; Linkov, I.; Asher, M.; Soslow, R.A. 2003: P53, beta-catenin and cyclin D1 are superior to p53 alone in distinguishing problematic uterine serous carcinomas from endometrioid carcinomas. Modern Pathology 16(1): 187A

Laurent, S.; De Saeger, C.; Lause, P.; Saliez, A.; Maiter, D.; Lambotte, L.; Horsmans, Y. 2000: P53, c-Ha-ras and IL-1beta after surgical procedures not inducing hepatocytes proliferation. Journal of Hepatology 32(Suppl 2): 166

Ishii, H.; Gobe, G.; Yoneyama, J.; Pan, W.; Kawakubo, Y.; Satoh, Y.; Ebihara, Y. 2000: P53, c-myc and bcl-2 Expression in gastric carcinomas with and without Epstein-Barr virus infection. Pathology International 50(Suppl): A88

Lauro, S.; Lanzetta, G.; Bria, E.; Trasatti, L.; Bordin, F.; Rocca, C.D.; Ramieri, M.T.; Agliano, A.; Gradilone, A.; Frati, L. 1999: P53, gp170 and K 19 as clinical prognostic factors for response in head and neck squamous cell carcinoma. European Journal of Cancer 35(Suppl 4): S177

Vahteristo, P.; Tamminen, A.; Karvinen, P.; Eerola, H.; Blomqvist, C.; Aittomaki, K.; Nevanlinna, H. 2001: P53, hCHK1, and hCHK2 genes in Finnish families with Li-Fraumeni syndrome; further evidence of hCHK2 in inherited cancer predisposition. European Journal of Human Genetics 9(Suppl 1): P0036

Giaccia, A. 2000: P53, hypoxia and malignant progression. Radiotherapy and Oncology 56(Suppl 1): S53

Al Othman, S.F.; Goepel, J.R.; Al Husaini, H.; Martin, J.; Saad Aldeen, J.A.; Lawry 2001: P53, mdm2, p21/waf1, bc12 and bcl-6 proteins expression in non-Hodgkins lymphomas. British Journal of Cancer 85(Suppl 1): 60

Lin, L.C.; Hwang, W.S.; Lee, P.S.; Hwang, C.T.; Que, J.; Lin, K.L.; Lin, F.C. 2003: P53, p21, p27 and bcl-2 as predictors for clinical outcome in rectal cancer. EJC Suppls 1(5): S86

Mcleish, R.; Southern, S.; Green, J.A.; Macdicken, I.A. 2002: P53, pRB and EGFr expression in relation to subtype in the transformation of cervical intraepithelial neoplasia. British Journal of Cancer 86(Suppl 1): S43

Sun, Y.; Cheung, H.S. 2002: P53, proto-oncogene and rheumatoid arthritis. Seminars in Arthritis and Rheumatism 31(5): 299-310

Steidl, C.; Truemper, L.H.; Haase, D. 2003: P53- and ATM-locus deletions in myelodysplastic syndromes and acute myeloid leukemias with complex karyotypes. Blood 102(11): 220b

Schneider Stock, R.; Boltze, C.; Peters, B.; Szibor, R.; Landt, O.; Roessner, A. 2002: P53-LOH in codon 72 of exon 4 in colorectal cancer and liver metastases is associated with preferential loss of the proline allele. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1141-1142

Hussain, S.P.; Amstad, P.; He, P.; Robles, A.; Lupold, S.; Sengupta, S.; Ichimiya, M.; Okamura, S.; Moake, M.; Forrester, K.; Harris, C.C. 2004: P53-Mediated oxidative stress and apoptosis. Toxicologic Pathology 32(1): 163-164

Duran, R.; Ortega, E.; Gil Hervas, P.; Paya, A.; Pico, C.; Laforga, J.B.; Aranda, F.I. 2001: P53-SSCP-LOH alterations and p53 overexpression in ductal infiltrating carcinoma of breast Correlation with clinicopathological variables. Virchows Archiv 439(3): 439

Hirabayashi, Y.; Yoshida, K.; Aizawa, S.I.; Kodama, Y.; Kanno, J.; Inoue, T. 2000: P53-deficiency directly revealed the non-threshold leukemogenesis by a single administration of relatively low-dose of methyl nitrosourea. Experimental Hematology 28(7 Suppl 1): 46

Dollinger, M.M.; Glazyrin, A.; Hayes, P.C.; Harrison, D.J. 2000: P53-dependent CD95-mediated apoptosis in primary murine hepatocytes is inducible by interferon-gamma and sensitive to cyclosporin A. Hepatology 32(4 Pt 2): 200A

Matsui, T.; Joh, T.; Fujita, F.; Okumura, F.; Watanabe, K.; Sasaki, M.; Seno, K.; Yokoyama, Y.; Nakanishi, M.; Itoh, M. 2002: P53-dependent Chk2 expression in gastric cancer, and study on the molecular mechanism. Gastroenterology 122(4 Suppl 1): A-237

Will, K.; Neben, M.; Schmidt Rose, T.; Wittern, K.P.; Deppert, W.; Bergemann, J. 1999: P53-dependent DNA damage response after ultraviolet B irradiation in skin cells - A useful indicator for UV-induced cellular stress and DNA damage. Journal of Investigative Dermatology 112(4): 657

Mayr, M.; Xu, Q. 2000: P53-dependent SMC apoptosis induced by mechanical stress is associated with mitochondrial alterations. Circulation 102(18): 2; 240

Kaminska, B. 2003: P53-dependent and -independent apoptosis of glioma cells. Molecular and Cellular Proteomics 2(9): 920

Oniscu, A.; Sphyris, N.; Morris, R.G.; Bader, S.; Harrison, D.J. 2003: P53-dependent and independent DNA damage responses in primary murine colonocytes A possible functional role for p73alpha. Journal of Pathology 201(Suppl): 6A

Taylor, W.R.; Beljin, M.; Clifford, B.; Stark, G.R. 2002: P53-dependent and independent pathways for G2 arrest in response to DNA damage. Proceedings of the American Association for Cancer Research Annual Meeting 43: 627

Nakamura, T.; Nakajima, Y.; Enomoto, T.; Westphal, H.; Murata, Y. 2000: P53-dependent and p53-independent apoptosis in the mouse lens epithelial cell tumor induced by CPT-11. Proceedings of the American Association for Cancer Research Annual Meeting 41: 300

Hasegawa, M.; Niibe, H.; Imai, R.; Nojima, K.; Maebayashi, K.; Suzuki, Y.; Takahashi, T.; Mitsuhashi, N.; Nakano, T. 2001: P53-dependent apoptosis induced by heavy-ion beams in human tumors in vivo. International Journal of Radiation Oncology Biology Physics 51(3 Suppl 1): 229-230

Shen, Y.; White, E. 2001: P53-dependent apoptosis pathways. Advances in Cancer Research 82: 55-84

Dbaibo, G.S.; El Assaad, W. 1999: P53-dependent ceramide generation in response to ionizing irradiation is caspase-mediated. FASEB Journal 13(7): A1343

Li, G.; Bush, J.; Ho, V. 1999: P53-dependent chemosensitivity in melanoma cells. Journal of Investigative Dermatology 112(4): 628

Pritchard, D.M.; Bower, L.; Jackman, A.L.; Hickman, J.A. 1999: P53-dependent cytotoxicity of 5-Fluorouracil and p53-independent cytotoxicity of Tomudex in human colon cancer cells. Gut 44(Suppl 1): A101

Liedtke, C.; Groger, N.; Manns, M.P.; Trautwein, C. 2002: P53-dependent gene transcription of the caspase-8 gene after adenovirale infection in human hepatoma cells. Hepatology 36(4 Part 2): 321A

Sun, S.Y.; Yue, P.; Hong, W.K.; Lotan, R. 2000: P53-dependent induction of Fas expression and augmentation of Fas/FasL-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting 41: 236

Wu, G.S.; Burns, T.F.; Meng, R.D.; El Deiry, W.S. 1999: P53-dependent induction of KILLER/DR5 in cells undergoing apoptosis but not cell cycle arrest. Proceedings of the American Association for Cancer Research Annual Meeting 40: 101

Kalka, K.; Ahmad, N.; Feyes, D.K.; Mukhtar, H. 1999: P53-dependent induction of WAF1/p21 during PDT-mediated apoptosis and ablation of mouse skin tumors. Photochemistry and Photobiology 69(SPEC ISSUE ): 7S

Donald, S.P.; Sun, X.Y.; Mei, J.M.; Phang, J.M. 1999: P53-dependent induction of proline oxidase and generation of reactive oxygen species in adriamycin-induced apoptosis. Proceedings of the American Association for Cancer Research Annual Meeting 40: 646

Burns, T.F.; Wu, G.S.; Kao, G.; Yen, T.; El Deiry, W.S. 1999: P53-dependent induction of the TRAIL receptor KILLER/DR5 is conserved in mouse cells and is deficient in cells from patients with ataxia telangiectasia. Proceedings of the American Association for Cancer Research Annual Meeting 40: 434

Hatashita, M.; Hayashi, S.; Jin, Z.H.; Matsumoto, H. 2003: P53-dependent regulation of induction of angiogenic regulatory factors by hyperthermia in vitro. Journal of Radiation Research 44(4): 426

Tsuchida, N.; Gao, C.F.; Zhang, L.; Watanabe, E.; Zhang, S.L.; Nakajima, T. 2001: P53-dependent transactivation-independent apoptosis in cells carrying temperature-sensitive p53. International Journal of Molecular Medicine 8(Suppl 1): S76

Narayan, S.; Kumar, V.; Jaiswal, A.S. 2001: P53-dependent transcriptional regulation of APC gene expression. Proceedings of the American Association for Cancer Research Annual Meeting 42: 219-220

Maclachlan, Timothy K.; Seth, Prem K.; El Deiry, Wafik S. 1999: P53-independent BRCA1-regulated expression of cellular genes. Proceedings of the American Association for Cancer Research Annual Meeting 40: 694

Burger, H.; Nooter, K.; Boersma, A.W.M.; Stoter, G. 1999: P53-independent apoptototic pathways in testicular germ cell tumor cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 40: 222

Abal, M.; Bras Goncalves, R.; Judde, J.G.; De Cremoux, P.; Louvard, D.; Magdelenat, H.; Robine, S.; Poupon, M.F. 2003: P53-independent cdk1 induction in response to irinotecan in the HT29 human colon cancer cell line. EJC Suppls 1(5): S289-S290

Ma, Y.; Yuan, R.; Meng, Q.; Goldberg, I.D.; Rosen, E.M.; Fan, S. 2000: P53-independent down-regulation of Mdm2 in human cancer cells treated with adriamycin. Molecular Cell Biology Research Communications: Mcbrc 3(2): 122-128

Garcia, J.; Schonthal, A.; Cadenas, E. 2000: P53-independent induction of p21, cell cycle arrest, and the specific targeting of cells endowed with an upregulated DT-diaphorase activity by 3,6-diaziridinyl-1,4-benzoquinone. Free Radical Biology and Medicine 29(Suppl 1): S133

Ivanchuk, S.; Mondal, S.; Stewart, C.; Rutka, J. 2001: P53-independent mechanism of ARF-mediated activity. Proceedings of the American Association for Cancer Research Annual Meeting 42: 168

Blaydes, J.P.; Darley, M. 2001: P53-independent regulation of Mdm-2 transcription in estrogen receptor-positive breast cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting 42: 624

Yamada, N.; Matsudaira, C.; Takahashi, K.; Inoue, H.; Seto, A.; Hayashi, S.; Jin, Z.H.; Hatashita, M.; Matsumoto, H. 2003: P53-independent thermo-chemo-sensitization by NO radical generators in transplanted tumors. Journal of Radiation Research 44(4): 425

Suaeyun, R.; Lunec, J. 2001: P53-independent transforming activity of MDM2 alternatively spliced variants and mRNA expression profiles. Proceedings of the American Association for Cancer Research Annual Meeting 42: 223

Polyak, K.; Vogelstein, B.; Kinzler, K.W. 2002: P53-induced apoptosis. Official Gazette of the United States Patent and Trademark Office Patents 1261(2)

Geske, F.J.; Nelson, A.C.; Lieberman, R.; Sun, T.; Strange, R.; Gerschenson, L.E. 1999: P53-induced apoptosis and DNA repair. FASEB Journal 13(5 Part 2): A816

Wiman, K.G.; Bykov, V.J.; Issaeva, N.; Shilov, A.; Bergman, J.; Selivanova, G. 2001: P53-induced apoptosis and new cancer therapy. European Journal of Cancer 37(Suppl 6): S139

Kaneko, I.; Ichimiya, M.; Chang, S.H.; Berezesky, I.K.; Trump, B.F.; Hussain, S.P.; Harris, C.C.; Amstad, P.A. 1999: P53-induced apoptosis is associated with the formation of reactive oxygen species and increased expression of manganese superoxide dismutase. FASEB Journal 13(4 Part 1): A518

Naumovski, L.; Rohde, L.H.; Ao, Y. 2000: P53-interacting protein Bbp/53BP2 sensitizes cells to doxorubicin-induced apoptosis through stimulation of p53 function. Proceedings of the American Association for Cancer Research Annual Meeting 41: 536

Liu, Y.angang; Kulesz Martin, Molly, F. 2003: P53-mediated apoptosis is compromised by defective binding to altered DNA structure. Proceedings of the American Association for Cancer Research Annual Meeting 44: 658

Unsal, K.; Morel, A.P.; Ponchel, F.; Glaise, D.; Guguen Guillouzo, C.; Carr, B.; Ozturk, M. 1999: P53-mediated growth arrest in Rb-negative cells. Dizdaroglu, M, Karakaya, A E NATO ASI Series Series A Life Sciences; Advances in DNA damage and repair: Oxygen radical effects, cellular protection, and biological consequences: 477-478

Gupta, S.; Colussi, V.C.; Feyes, D.K.; Greenberg, N.M.; Mukhtar, H. 1999: P53-mediated induction of p21/WAF1 and apoptosis during phthalocyanine photodynamic therapy of prostate cancer in transgenic mice. Photochemistry and Photobiology 69(SPEC ISSUE ): 8S

Barboza, J.A.; Lozano, G. 2003: P53-mediated phenotypes in the absence of MDM2 versus MDMX. Proceedings of the American Association for Cancer Research Annual Meeting 44: 656-657

Saifudeen, Zubaida; Du, Hong; Dipp, Susana; El Dahr, Samir S. 2001: P53-mediated regulation of proliferating cell nuclear antigen gene expression during kidney development. Pediatric Research 49(4 Part 2): 419A

Becker, A.; Krause, U.; Stadler, P.; Haensgen, G.; Feldmann, H.; Molls, M.; Dunst, J. 2000: P53-overexpression and polarographically measured tumor-pO2 in squamous cell carcinoma of the head and neck. International Journal of Radiation Oncology Biology Physics 48(3 Suppl): 280-281

Zigeuner, R.E.; Schips, L.; Lipsky, K.; Rehak, P.; Hubmer, G.; Ratschek, M.; Langner, C. 2003: P53-overexpression in renal cell carcinoma is associated with histological subtypes. Journal of Urology 169(4 Suppl): 199

Satoh, K.; Kihira, K.; Kawata, H.; Fukazawa, K.; Kawakami, S.; Kumakura, Y.; Tokumaru, K.; Ishino, Y.; Kojima, T.; Sugano, K. 2000: P53-positive cells in the gastric mucosa before and after Helicobacter pylori eradication. Gastroenterology 118(4 Suppl 2 Pt 1): AGA A751

Leung, W.K.; Gutierrez, O.; Genta, R.M.; Graham, D.Y.; Sepulveda, A.R. 1999: P53-positive gastric cancer is infrequently associated with p53-positive intestinal metaplasia. Gastroenterology 116(4 Part 2): A452

Levine, A.J.; Murphy, M.E.; Mack, D.H.; Gish, K.C.; Tom, E.Y. Wah 2000: P53-regulated genes. Official Gazette of the United States Patent and Trademark Office Patents 1231(1)

Thomson, K.; Margison, G.P.; Santibanez Koref, M.; Rafferty, J.A. 1999: P53-regulated induction of O6-alkylguanine-DNA-alkyltransferase in response to DNA damage. Proceedings of the American Association for Cancer Research Annual Meeting 40: 740

Ramachandra, M.; Zou, A.; Rahman, A.; Vaillancourt, M.; Horn, M.; Neugebauer, S.; Sugarman, B.; Howe, J.; Johnson, D.; Engler, H.; Demers, G.W.; Shabram, P. 2001: P53-regulated selectively attenuated oncolytic adenovirus vectors. Proceedings of the American Association for Cancer Research Annual Meeting 42: 32

Ramachandra, M.; Rahman, A.; Zou, A.; Vaillancourt, M.; Horn, M.; Neugebauer, S.; Sugarman, B.; Howe, J.; Faha, B.; Johnson, D.; Engler, H.; Demers, W.; Ralston, R.; Shabram, P. 2000: P53-regulated selectively replicating adenovirus vectors. Cancer Gene Therapy 7(12): S9

Yu, G.Y.; Kho, P.; Wang, Z.; Zhuang, L.; Liu, E.T. 2003: P53-regulated transcriptional program implicated in genotoxic stress-induced apoptosis. Analytical Cellular Pathology 25(5-6): 262

Ellenhorn, J.D.I.; Diamond, D.J. 2004: P53-specific T cell receptor for adoptive immunotherapy. Official Gazette of the United States Patent and Trademark Office Patents 1285(1)

Querec, T.D.; Stewart, S.L.; Gruver, B.N.; Stoyanova, R.S.; Ross, E.; Frolov, A.; Engstom, P.; Godwin, A.; Patriotis, C. 2002: P53/DNA-PK-dependent Fenretinide-induced apoptosis in normal and malignant human ovarian surface epithelial cells. Proceedings of the American Association for Cancer Research Annual Meeting 43: 458

Bakkar, Ashraf; Wallerand, Herve; Lahaye, Jean Baptiste; Pairon, Jean Claude Sr.; Radvanyi, Francois Sr.; Jaurand, Marie Claude; Thiery, Jean Paul; Chopin, Dominique K.; De Medina, Sixtina Gil Diez 2003: P53/FGFR3 mutations characterize two different molecular pathways at initial diagnosis in transitional cell carcinoma. Proceedings of the American Association for Cancer Research Annual Meeting 44: 99

Giordana, M.T.; Pradotto, L.; Morra, I.; Duo, D.; Boghi, A.; Mauro, A. 2000: P53/MDM2 interaction and prognosis in medulloblastoma. Tumori 86(4 Suppl 1): 30-31

Arribas, B.; Cristobal, E.; Alcazar, J.A.; Martinez, J.C.; Polo, J.R.; Tardio, J.; Carrion, R.; Menarguez, J. 1999: P53/MDM2 pathway aberrations in parathyroid pathology p21WAF1 and MDM2 are frequently upregulated in parathyroid adenomas. Virchows Archiv 435(3): 221

D.O., M.P.; Cavalcanti, G.; Fernandes, M.A.; Klumb, C.E.; Maia, R.C.; Dobbin, J.; Rios, M. 2002: P53/p16 analysis in Brazilian adult t-cell leukemia patients. International Journal of Cancer Suppl (13): 392

D.B.er, R.H.; Johnston, S.R.D.; Walton, M.; Salter, J.; Dowsett, M.; Gore, M. 1999: P53/p21 immunophenotype predicts for resistance to single-agent platinum in ovarian cancer. British Journal of Cancer 80(Suppl 2): 72

Arakawa, H.; Matsuda, K.; Tanaka, T.; Oda, K.; Takada, T.; Nishioka, Y.; Taya, Y.; Nakamura, Y. 2001: P53AIP1, a potential mediator of p53-dependent apoptosis Its regulation by Ser-46-phosphorylated p53 and interaction with bcl-2 at mitochondria. Proceedings of the American Association for Cancer Research Annual Meeting 42: 419

Lima, Carmen S.P.; Ortega, Manoela M.; Melo, Monica B.; Lorand Metze, Irene; De Souza, Carmino A.; Costa, Fernando F. 2002: P53Gene Deletion as a Prognostic Factor in Multiple Myeloma. Blood 100(11): Abstract No. 5079

Mcdonald, S.P.; Duarte, N.; Walsh, W.F.; Wilcken, D.E.L.; Hoy, W.E.; Wang, X.L. 2001: P53Pro72Arg polymorphism is associated with albuminuria among Aboriginal Australians. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 557A

Purpi, D.; Wong, S. 2003: P53R2 gene expression modulates growth effects of gemcitabine in head and neck cancer cells following radiation. International Journal of Radiation Oncology Biology Physics 57(2 Suppl): S349

Tanikawa, C.; Matsuda, K.; Fukuda, S.; Nakamura, Y.; Arakawa, H. 2003: P53RDL1UNC5B as a positive and negative regulator of p53-dependent apoptosis. Proceedings of the American Association for Cancer Research Annual Meeting 44: 657

Blenis, J.; Lee Fruman, K.K.; Kuo, C.J. 2002: P54s6k and p85s6k genes, proteins, primers, probes, and detection methods. Official Gazette of the United States Patent and Trademark Office Patents 1257(3)

Almeida, D.S.lva, P.; Bigi, F.; Santangelo, M.D.P.; Cataldi, A.A.; Martin, C. 2000: P55 from Mycobacterium tuberculosis is an antibiotic efflux pump. Abstracts of the General Meeting of the American Society for Microbiology 100: 642

Kim, S.H.; Shin, C.R. 2001: P55CDC mutant induces G1 arrest in nocodazole-treated cells. Molecular Biology of the Cell 12(Suppl): 278a-279a

Lin, M.L.; Kao, C.; Weinstein, J.; Sakamoto, K.M. 1999: P55CDC overexpressing results in premature cell cycle transition from G1 to S phase. Journal of Investigative Medicine 47(2): 61A

Garbarino, J.E.; Gibbons, I.R. 2001: P560, a novel and highly conserved AAA protein related to dynein, is required for viability. Molecular Biology of the Cell 12(Suppl): 448a-449a

Blakely, E.A.; Chang, P.Y.; Mcnamara, M.P.; Bjornstad, K.A. 2001: P57KIP2 and E2F1 expression in differentiating cultured human lens epithelial cells. IOVS Investigative Ophthalmology and Visual Science 42(4): S310

Weksberg, R.; Li, M.; Fei, Y.L.; Shuman, C.; Chitayat, D.; Atkin, J.; Pauli, R.M.; Squire, J.A. 2000: P57KIP2 mutations associated with loss of IGF2 imprinting in Beckwith-Wiedemann syndrome. American Journal of Human Genetics 67(4 Suppl 2): 392

Maclean, H.E.; Cobrinik, D.; Zhang, P.; Kronenberg, H.M. 2001: P57Kip2, and p107 and p130, regulate chondrocyte proliferation in vivo, and may be targets of PTHrP action. Journal of Bone and Mineral Research 16(Suppl 1): S161

Popiolek, D.; Yee, H.; Perle, M.A.; Mittal, K.; Demopoulos, R.I. 2002: P57kip2 a maternally imprinted cdk inhibitor, a useful marker for separating complete mole from other gestations with changes suggestive of molar pregnancy/chromosomal abnormalities. Laboratory Investigation 82(1): 206A-207A

Sinuani, I.; Averbukh, Z.; Gitelman, I.; Kalechman, Y.; Sredni, B.; Weissgarten, J. 2003: P57kip2 is pivotal factor in compensatory tubular cell hypertrophy. Journal of the American Society of Nephrology 14(Abstracts Issue): 328A

Goodman, A.G.; Korth, M.J.; Baskin, C.R.; Morton, J.; Ladiges, W.; Katze, M.G. 2004: P58IPK, a potential virulence factor that regulates influenza viral protein synthesis. Biophysical Journal 86(1): 89a

Schmidt, D.J.; Hartmann, R.; Jcrgensen, R.; Justesen, J. 1999: P59OASL, an interferon induced 2-5 oligoadenylate synthetase-like protein. Journal of Interferon and Cytokine Research 19(Suppl 1): S150

Faupel Badger, J.M.; Danielsen, A.J.; Magnuson, T.; Maihle, N.J. 2002: P60 sEGFR/ErbB1, a novel isoform of the human EGFR, functions as a matricellular protein. Proceedings of the American Association for Cancer Research Annual Meeting 43: 331

Faupel Badger, J.M.; Danielson, A.J.; Juneja, S.C.; Reiter, J.L.; Green, P.; Magnuson, T.; Maihle, N.J. 2001: P60 sErbB1 negatively regulates epidermal growth factor receptor signaling. Proceedings of the American Association for Cancer Research Annual Meeting 42: 958

Juneja, S.C.; Reiter, J.L.; Faupel Badger, J.M.; Grande, J.P.; Green, P.; Magnuson, T.R.; Maihle, N.J. 2000: P60 sErbB1/EGFR transgenic mice are lactation defective and exhibit altered mammary gland morphology. Molecular Biology of the Cell 11(Suppl): 62a-63a

Seva, C.; Kowalski Chauvel, A.; Daulhac, L.; Huc, L.; Vaysse, N.; Pradayrol, L. 2000: P60-src and p125-FAK are potential mediators of PI 3-kinase activation by glycine-extended gastrin precursors. Gastroenterology 118(4 Suppl 2 Pt 1): AGA A437

Chang, S.; Park, J.; Shin, J. 2001: P62 interacts with prostate apoptosis response-4 and forms ternary complex with protein kinase C-zeta. FASEB Journal 15(4): A10

Shin, J.; Joung, I.; Vadlamudi, R.K.; Strominger, J.L. 2001: P62 polypeptides, related polypeptides, and uses therefor. Official Gazette of the United States Patent and Trademark Office Patents 1250(3)

Stumptner, C.; Zatloukal, K.; Fickert, P.; Denk, H. 1999: P62/A170 A novel component of Mallory Bodies associated with alcoholic hepatitis. Hepatology 30(4 Part 2): 551A

Paulk, J.M.; Wooten, M.W. 2001: P62/ZIP plays a role in regulation of NGF-mediated NF-kappaB activation. FASEB Journal 15(5): A1163

Niki, M.; Hirai, H.; Paolo, P.P.er 2003: P62dok and p56dok-2 oppose leukemogenesis by p210Bcr-Abl. Blood 102(11): 650a-651a

Yang, A.; Wang, Y.; Sun, D.; Park, J.; Quade, B.J.; Mckeon, F.D.; Crum, C.P. 1999: P63 A p53 homologue that is a differentiation-specific marker in cervical squamous epithelium. Modern Pathology 12(1): 178A

Thurfjell, N.; Coates, P.J.; Uusitalo, T.; Mahani, D.; Dabelsteen, E.; Dahlqvist, A.; Sjostrom, B.; Roos, G.; Nylander, K. 2003: P63 a relative of p53-from a general and oral aspect. International Journal of Molecular Medicine 12(Suppl 1): S8

Wu, M.; Wang, B.Y.; Gil, J.; Miller, L.; Gan, L.; Burstein, D.E. 2002: P63 and TTF-1 immunostaining A valuable marker panel for distinguishing small cell carcinoma from poorly differentiated squamous cell carcinoma of lung. Laboratory Investigation 82(1): 330A

Marin, M.C.; Kaelin, W.G. 2000: P63 and p73: old members of a new family. Biochimica et Biophysica Acta 1470(3): M93

Pecciarini, L.; Cangi, M.G.; Signoretti, S.; Rizzo, A.; Canal, F.; Chilosi, M.; Doglioni, C. 2001: P63 expression in human high grade lymphomas. Proceedings of the American Association for Cancer Research Annual Meeting 42: 334